Disease overview

Alterations

106

Molecular (A)

100

Clinical (B–E)

Direct drugs

1036

Via biomarker

432

Natural agents

Natural products

107

Merged ranked

1462

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, PubMed NP, ClinicalTrials.gov NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Spontaneous regression documented but rare (<0.5%); 5-year survival stage I: ~99%; stage IV: ~28% overall, improving with modern therapy

Best-intervention remission

HER2+ metastatic: pertuzumab + trastuzumab + docetaxel (CLEOPATRA: 57.1-month median OS vs 40.8 months); HR+/HER2- with CDK4/6 inhibitors: 63-month PFS in first-line (MONALEESA-2); TNBC with pembrolizumab + chemotherapy: 23-month OS vs 16.1 months; pCR with neoadjuvant: 80-90% in HER2+ with dual HER2 blockade

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Varies greatly by subtype; HER2+ and HR+ have dramatically improved outcomes; TNBC lags; metastatic remains incurable in most patients

Primary barrier

biological (metastatic) + access (treatment disparities by race/SES)

Barrier detail: Racial disparities in breast cancer mortality persist (Black women 40% higher mortality despite similar incidence); access to genetic testing (BRCA1/2) and CDK4/6 inhibitors varies significantly; germline testing vastly underutilised

Last SoC change: 2023 — antibody-drug conjugates (ADCs) transforming TNBC (sacituzumab govitecan 2020, trastuzumab deruxtecan for HER2-low 2022); olaparib adjuvant in BRCA-mutated HER2- (OlympiA 2021); CDK4/6 inhibitors first-line HR+/HER2- since 2015; trastuzumab HER2+ since 1998

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0007254 · ORPHA: ORPHA:227535

Alterations

106 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Breast carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
AKT1 AKT serine/threonine kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AKT2 AKT serine/threonine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AKT3 AKT serine/threonine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AR androgen receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1A AT-rich interaction domain 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATM ATM serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BARD1 BRCA1 associated RING domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BLM BLM RecQ like helicase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA1 BRCA1 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA2 BRCA2 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRIP1 BRCA1 interacting DNA helicase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C11orf65 chromosome 11 open reading frame 65	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1D calcium voltage-gated channel subunit alpha1 D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CBFB core-binding factor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCND1 cyclin D1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD274 CD274 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDC73 cell division cycle 73	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDH1 cadherin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK4 cyclin dependent kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK6 cyclin dependent kinase 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN1B cyclin dependent kinase inhibitor 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK2 checkpoint kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CUX1 cut like homeobox 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP19A1 cytochrome P450 family 19 subfamily A member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DROSHA drosha ribonuclease III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EBF1 EBF transcription factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EGFR epidermal growth factor receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB2 erb-b2 receptor tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB4 erb-b2 receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR2 estrogen receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FANCC FA complementation group C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FANCD2 FA complementation group D2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FBXO11 F-box protein 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR2 fibroblast growth factor receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR4 fibroblast growth factor receptor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FHIT fragile histidine triad diadenosine triphosphatase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOXA1 forkhead box A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOXP1 forkhead box P1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FTO FTO alpha-ketoglutarate dependent dioxygenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GATA3 GATA binding protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
H3C2 H3 clustered histone 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDR kinase insert domain receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KMT2C lysine methyltransferase 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP2K4 mitogen-activated protein kinase kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP3K1 mitogen-activated protein kinase kinase kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MLH1 mutL homolog 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MLLT10 MLLT10 histone lysine methyltransferase DOT1L cofactor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MRTFA myocardin related transcription factor A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MSH2 mutS homolog 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MSH6 mutS homolog 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MUTYH mutY DNA glycosylase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NBN nibrin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NCOR1 nuclear receptor corepressor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NF1 neurofibromin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH2 notch receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NTRK3 neurotrophic receptor tyrosine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Overall survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PALB2 partner and localizer of BRCA2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PAX5 paired box 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PMS2 PMS1 homolog 2, mismatch repair system component	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD1 DNA polymerase delta 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLE DNA polymerase epsilon, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPM1D protein phosphatase, Mg2+/Mn2+ dependent 1D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRIM1 DNA primase subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTEN phosphatase and tensin homolog	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Progression-free Survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
RAD50 RAD50 double strand break repair protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RAD51 RAD51 recombinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RAD51B RAD51 paralog B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RAD51C RAD51 paralog C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RAD51D RAD51 paralog D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RB1 RB transcriptional corepressor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RET ret proto-oncogene	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RRM2 ribonucleotide reductase regulatory subunit M2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SETBP1 SET binding protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SF3B1 splicing factor 3b subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TACSTD2 tumor associated calcium signal transducer 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TBX3 T-box transcription factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TCF7L2 transcription factor 7 like 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TERT telomerase reverse transcriptase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TET2 tet methylcytosine dioxygenase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TOP1 DNA topoisomerase I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TOP2A DNA topoisomerase II alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TP53 tumor protein p53	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1A tubulin alpha 1a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1B tubulin alpha 1b	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1C tubulin alpha 1c	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA3E tubulin alpha 3e	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA4A tubulin alpha 4a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB tubulin beta class I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB1 tubulin beta 1 class VI	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB2A tubulin beta 2A class IIa	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB2B tubulin beta 2B class IIb	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB3 tubulin beta 3 class III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB6 tubulin beta 6 class V	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TYMS thymidylate synthetase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VEGFA vascular endothelial growth factor A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ZFHX3 zinc finger homeobox 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
complications	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
disease-free survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
time to progression	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
BICALUTAMIDE	Small molecule	Approved	Strong	105	8 trials 3 Trial pubs View evidence Registry trials NCT02605486 — Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT05095207 — Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer (RECRUITING) PHASE1, PHASE2 NCT06365788 — Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer (RECRUITING) PHASE2 NCT03650894 — Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (ACTIVE_NOT_RECRUITING) PHASE2 NCT00590213 — Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX (COMPLETED) PHASE4 NCT00468715 — Bicalutamide in Treating Patients With Metastatic Breast Cancer (COMPLETED) PHASE2 NCT06727357 — Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP (ACTIVE_NOT_RECRUITING) PHASE2 NCT03055312 — Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer (TERMINATED) PHASE3 Published literature Clinical trial publication Serial [(18)F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer (European journal of cancer (Oxford, England : 1990), 2021) Clinical trial publication Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer (The oncologist, 2020) Clinical trial publication Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer (Clinical cancer research : an official journal of the American Association for Cancer Research, 2013) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EPIRUBICIN	Small molecule	Approved	Strong	105	8 trials 11 Cochrane 21 Meta-analysis 975 Trial pubs 561 RCT View evidence Registry trials NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT02115152 — Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer (UNKNOWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 NCT05909332 — Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) (RECRUITING) PHASE3 NCT01996267 — Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (ACTIVE_NOT_RECRUITING) PHASE3 NCT00003012 — Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer (COMPLETED) PHASE3 NCT01159236 — Molecular Triaging of Newly Diagnosed Breast Cancer (WITHDRAWN) NA Published literature Cochrane review Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials (Cardio-oncology (London, England), 2025) Cochrane review Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis (BMC women's health, 2025) Cochrane review The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis (Current oncology (Toronto, Ont.), 2024) Cochrane review Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis (Cancer medicine, 2024) Cochrane review Effects of Integrated Chinese Traditional Medicine and Conventional Western Medicine on the Quality of Life of Breast Cancer Patients: A Systematic Review and Meta-Analysis (Evidence-based complementary and alternative medicine : eCAM, 2022) Meta-analysis Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer (World journal of surgical oncology, 2021) Meta-analysis Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021) Systematic review [Effect of taste perception on nutritional status in patients with breast cancer: a systematic review] (Nutricion hospitalaria, 2025) Clinical trial publication Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA) (JCO global oncology, 2026) Clinical trial publication Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Clinical trial publication Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (Annals of surgical oncology, 2026) Clinical trial publication Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial (BMJ (Clinical research ed.), 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	105	8 trials 2 Trial pubs View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT03805399 — FUSCC Refractory TNBC Umbrella (FUTURE) (UNKNOWN) PHASE1, PHASE2 NCT02520063 — Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT01088893 — Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy (UNKNOWN) PHASE2 NCT03659136 — The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread (COMPLETED) PHASE2 NCT05983107 — Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (RECRUITING) PHASE2 NCT01111825 — Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT02809404 — Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) (COMPLETED) Published literature Systematic review mTOR inhibitors in breast cancer: a systematic review (Gynecologic oncology, 2012) Clinical trial publication Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy (Breast cancer research and treatment, 2015) Clinical trial publication Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer (Investigational new drugs, 2010) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FLUMAZENIL	Small molecule	Approved	Strong	100	1 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT05435911 — Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol (COMPLETED) NA Published literature Clinical trial publication Effects of remimazolam vs. an etomidate-propofol mixture on postoperative cognitive function in elderly female patients undergoing radical mastectomy for breast cancer: a randomized controlled trial (Frontiers in medicine, 2025) Clinical trial publication Comparison of recovery profiles between total intravenous anaesthesia with propofol or remimazolam reversed with flumazenil in patients undergoing breast surgery: A randomised controlled trial (European journal of anaesthesiology, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
METHOXSALEN	Small molecule	Approved	Strong	100	2 trials View evidence Registry trials NCT04389281 — X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (RECRUITING) PHASE1 NCT04720664 — Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APIGENIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASTEMIZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATRACURIUM BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENORILATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BEXAROTENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BIFONAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BISACODYL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BLEOMYCIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUPRENORPHINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUTAMBEN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCIFEDIOL ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCIPOTRIENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCITRIOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANRENONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPIVASERTIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing	Small molecule	Approved	Strong	95	8 trials 24 Cochrane 30 Meta-analysis 416 Trial pubs 172 RCT View evidence Registry trials NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (RECRUITING) NA NCT06400472 — A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (RECRUITING) PHASE1 NCT00002628 — Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer (UNKNOWN) PHASE1, PHASE2 NCT04681911 — Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT03134638 — A Study of SY-1365 in Adult Patients With Advanced Solid Tumors (TERMINATED) PHASE1 NCT01560663 — Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer (UNKNOWN) NCT05430347 — Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer (UNKNOWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 Published literature Cochrane review Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis (Expert review of anticancer therapy, 2026) Cochrane review Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis (Discover oncology, 2025) Cochrane review Efficacy and safety of neoadjuvant ICI combined with chemotherapy in breast cancer from the perspective of a privileged population: a systematic review and meta-analysis (International journal of surgery (London, England), 2025) Cochrane review Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis (Current problems in cancer, 2024) Cochrane review Platinum-based chemotherapy for early triple-negative breast cancer (The Cochrane database of systematic reviews, 2023) Meta-analysis Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: An updated systematic review and meta-analysis (Medicine, 2025) Meta-analysis Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis (Breast cancer research and treatment, 2025) Meta-analysis The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis (Scientific reports, 2025) Systematic review A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence (International journal of molecular sciences, 2026) Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer (ESMO open, 2026) Clinical trial publication Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study (Breast cancer research and treatment, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
CARFILZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CEFONICID SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CEFPODOXIME PROXETIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CERIVASTATIN SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CHENODEOXYCHOLIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORDIAZEPOXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORHEXIDINE GLUCONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORMADINONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CHLOROTRIANISENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROXINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORPROMAZINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CHOLECALCIFEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CICLESONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	8 trials 17 Cochrane 14 Meta-analysis 328 Trial pubs 95 RCT View evidence Registry trials NCT07372079 — Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy (NOT_YET_RECRUITING) PHASE2 NCT00191854 — Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line (COMPLETED) PHASE2 NCT02544243 — Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT06746870 — A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer (NOT_YET_RECRUITING) PHASE2 NCT00003269 — Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors (COMPLETED) PHASE2 NCT03387085 — QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (TERMINATED) PHASE1, PHASE2 NCT04159818 — Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (RECRUITING) PHASE2 NCT02879513 — Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy (UNKNOWN) PHASE3 Published literature Cochrane review Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis (Discover oncology, 2025) Cochrane review Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis (Current problems in cancer, 2024) Cochrane review Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis (Cancer pathogenesis and therapy, 2024) Cochrane review 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023) Cochrane review Platinum-based chemotherapy for early triple-negative breast cancer (The Cochrane database of systematic reviews, 2023) Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors (Cancer medicine, 2026) Meta-analysis Are hydrogels suitable for delivery of cisplatin to the microenvironment in breast cancer treatment: a meta-analysis (Therapeutic delivery, 2025) Meta-analysis Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis (European urology oncology, 2024) Meta-analysis The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis (Medicine, 2022) Systematic review Reawakening the master switches in triple-negative breast cancer: A strategic blueprint for confronting metastasis and chemoresistance via microRNA-200/205: A systematic review (Critical reviews in oncology/hematology, 2024) Clinical trial publication A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer (ESMO open, 2026) Clinical trial publication Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial (Scientific reports, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
CLASCOTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOBETASOL PROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOCORTOLONE PIVALATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CLOFARABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CLOTRIMAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CODEINE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
COLCHICINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CROMOLYN SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CYCLANDELATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYPROTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DACTINOMYCIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DANAZOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAROLUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAUNORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT06190600 — Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy (ACTIVE_NOT_RECRUITING) NA NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT00944047 — Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression (COMPLETED) PHASE2 NCT01697293 — PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (TERMINATED) PHASE1, PHASE2 NCT00574236 — Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer (TERMINATED) PHASE2 NCT02115152 — Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer (UNKNOWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
DAUNORUBICIN LIPOSOMAL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEFERASIROX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEFLAZACORT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DESERPIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DESLANOSIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DESOGESTREL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DESONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DESOXIMETASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DESOXYCORTICOSTERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DESOXYCORTICOSTERONE PIVALATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DEXAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIDANOSINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLCARBAMAZINE CITRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIFLORASONE DIACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIFLUPREDNATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIGITOXIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIGOXIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIPHENOXYLATE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DIPYRIDAMOLE Repurposing	Small molecule	Approved	Strong	95	3 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Myocardial perfusion imaging in breast cancer patients treated with or without post-mastectomy radiotherapy (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2000) Clinical trial publication Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer (Investigational new drugs, 1994) Clinical trial publication Phase I trial of dipyridamole with 5-fluorouracil and folinic acid (Cancer research, 1990) CT.gov search · Cochrane · PubMed	DGIdb	—
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOFETILIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	8 trials 1 Meta-analysis 6 Trial pubs 5 RCT View evidence Registry trials NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (RECRUITING) NA NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT02423356 — Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin (COMPLETED) NCT00584766 — Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer (COMPLETED) PHASE2 NCT06190600 — Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy (ACTIVE_NOT_RECRUITING) NA NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT00944047 — Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression (COMPLETED) PHASE2 NCT01697293 — PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (TERMINATED) PHASE1, PHASE2 Published literature Meta-analysis Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens (British journal of cancer, 1993) Clinical trial publication Bioequivalence of two doxorubicin liposome formulations (LY01612 and Caelyx) using free and encapsulated doxorubicin concentrations in Chinese patients with advanced breast cancer (International journal of clinical pharmacology and therapeutics, 2025) Clinical trial publication A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer (Journal of cancer research and clinical oncology, 2025) Clinical trial publication Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study (Breast cancer research and treatment, 2023) Clinical trial publication Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial (JAMA surgery, 2020) Clinical trial publication Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results (JAMA, 1995) CT.gov search · Cochrane · PubMed	DGIdb	—
DROMOSTANOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DRONEDARONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DROSPIRENONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DULOXETINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DURVALUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DUTASTERIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DYCLONINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DYDROGESTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ECONAZOLE NITRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EFAVIRENZ Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENZALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIGALLOCATECHIN GALLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOCALCIFEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ERLOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRADIOL 3-BENZOATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRADIOL CYPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRADIOL VALERATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRAMUSTINE PHOSPHATE SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ESTRIOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHACRYNIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHINYL ESTRADIOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHYLESTRENOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHYNODIOL DIACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ETONOGESTREL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ETOPOSIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EVEROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EXEMESTANE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EXIFONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FEBUXOSTAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOFIBRATE MICRONIZED Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOLDOPAM MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FENTANYL CITRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FEPRAZONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FINASTERIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUCYTOSINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUDARABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUDROCORTISONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUNISOLIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOCINOLONE ACETONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOCINONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOROMETHOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOROURACIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOXETINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FLUOXYMESTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUPREDNISOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FLURANDRENOLIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUSPIRILENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FULVESTRANT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GEFITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GEMCITABINE Repurposing	Small molecule	Approved	Strong	95	8 trials 8 Cochrane 13 Meta-analysis 323 Trial pubs 103 RCT View evidence Registry trials NCT04681911 — Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT01133912 — Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) (COMPLETED) PHASE1 NCT00662129 — Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer (COMPLETED) PHASE2 NCT00191854 — Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line (COMPLETED) PHASE2 NCT02046421 — Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (COMPLETED) PHASE1 NCT02139358 — Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT02544243 — Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT06481553 — RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody (UNKNOWN) Published literature Cochrane review Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials (Medicina (Kaunas, Lithuania), 2024) Cochrane review Radiation recall dermatitis: A review of the literature (Seminars in oncology, 2022) Cochrane review Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer (BMC cancer, 2021) Cochrane review The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety (Oncology research and treatment, 2021) Cochrane review Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis (Pharmacotherapy, 2019) Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors (Cancer medicine, 2026) Systematic review Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review (The Lancet. Oncology, 2011) Systematic review The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review (European journal of cancer (Oxford, England : 1990), 2009) Systematic review Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer (Journal of the National Cancer Institute, 2008) Systematic review Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review (Health technology assessment (Winchester, England), 2008) Clinical trial publication A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer (ESMO open, 2026) Clinical trial publication Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study (Annals of oncology : official journal of the European Society for Medical Oncology, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
GEMCITABINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GENTIAN VIOLET CATION Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GESTODENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GLUTATHIONE DISULFIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GLYCYRRHIZIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GRISEOFULVIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HALCINONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HALOBETASOL PROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HALOPERIDOL DECANOATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HALOPROGIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HEXACHLOROPHENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROCORTISONE BUTYRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE PROBUTATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE SODIUM PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE SODIUM SUCCINATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE VALERATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROXYUREA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IBRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IDARUBICIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IDARUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
IDEBENONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDINAVIR SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IOPAMIDOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IPILIMUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IRINOTECAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOPROPYL UNOPROSTONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOTRETINOIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LACTATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEUCOVORIN CALCIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEUPROLIDE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVODOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LIOTHYRONINE SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOPERAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LORACARBEF Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LORATADINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOTEPREDNOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOVASTATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LULICONAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAPROTILINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MASOPROCOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECHLORETHAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEDRYSONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEGESTROL ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MELOXICAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MELPHALAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHOBARBITAL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPREDNISONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MESTRANOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METFORMIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHANDROSTENOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLDOPA ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLENE BLUE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHYLENE BLUE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHYLPREDNISOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLPREDNISOLONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHYLTESTOSTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METIPRANOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIBEFRADIL DIHYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MIDAZOLAM HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MIFEPRISTONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MILTEFOSINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MINOCYCLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MITOMYCIN Repurposing	Small molecule	Approved	Strong	95	4 trials 119 Trial pubs 60 RCT View evidence Registry trials NCT01196455 — Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT02299999 — SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT01091168 — Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer (COMPLETED) PHASE3 NCT00003893 — Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer (COMPLETED) PHASE3 Published literature Systematic review A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer (Health technology assessment (Winchester, England), 2000) Clinical trial publication Role of Mitomycin C in Preventing Capsular Contracture in Implant-Based Reconstructive Breast Surgery: A Randomized Controlled Trial (Plastic and reconstructive surgery, 2017) Clinical trial publication Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer (Onkologie, 2012) Clinical trial publication Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer (Breast cancer research : BCR, 2012) Clinical trial publication Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer (Neoplasma, 2011) Clinical trial publication Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer (European radiology, 2010) Randomized controlled trial Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer (The American journal of Chinese medicine, 2008) Randomized controlled trial Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival (Annals of oncology : official journal of the European Society for Medical Oncology, 2005) CT.gov search · Cochrane · PubMed	DGIdb	—
MITOTANE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MITOXANTRONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MITOXANTRONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	8 trials 5 Trial pubs 2 RCT View evidence Registry trials NCT06156761 — Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer (UNKNOWN) NA NCT02596373 — A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT00002498 — Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer (UNKNOWN) PHASE2 NCT00002544 — Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer (COMPLETED) PHASE3 NCT00010075 — Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT04927481 — A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer (TERMINATED) PHASE2 NCT00003068 — High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer (COMPLETED) PHASE2 NCT05582499 — Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (RECRUITING) PHASE2 Published literature Clinical trial publication Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study (BMC medicine, 2026) Clinical trial publication Discovery of fluorescent properties in mitoxantrone hydrochloride injection for tracing: application for sentinel lymph node biopsy in breast cancer (World journal of surgical oncology, 2026) Clinical trial publication A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer (BMC cancer, 2025) Clinical trial publication Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial (Investigational new drugs, 2022) Clinical trial publication 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer (Breast cancer (Tokyo, Japan), 2001) CT.gov search · Cochrane · PubMed	DGIdb	—
MITOXANTRONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MOCLOBEMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOMETASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MORICIZINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MYCOPHENOLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MYCOPHENOLATE MOFETIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NAFTIFINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NANDROLONE DECANOATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NANDROLONE PHENPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEFAZODONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NELFINAVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NICARDIPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NICARDIPINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NICOTINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NIFEDIPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NILUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NINTEDANIB ESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NIRAPARIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NISOLDIPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NITAZOXANIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NITROFURAZONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NIVOLUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORELGESTROMIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORETHINDRONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORETHINDRONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORETHYNODREL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORGESTIMATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORGESTREL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORTRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
O-PHENANTHROLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OCTOCRYLENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLAPARIB Repurposing	Small molecule	Approved	Strong	95	8 trials 8 Cochrane 12 Meta-analysis 64 Trial pubs 26 RCT View evidence Registry trials NCT06197581 — Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RECRUITING) NA NCT06797635 — Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (RECRUITING) PHASE2 NCT01445418 — AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer (COMPLETED) PHASE1 NCT06175390 — Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT00516724 — Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel (COMPLETED) PHASE1 NCT05174832 — Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients (UNKNOWN) PHASE2 NCT02898207 — Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (COMPLETED) PHASE1 NCT02561832 — A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer (TERMINATED) PHASE1 Published literature Cochrane review Dose reduction of olaparib in older patients: Insights from an analysis of a National Database in Japan (The journal of obstetrics and gynaecology research, 2023) Cochrane review PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis (Hematology/oncology and stem cell therapy, 2023) Cochrane review Cost-effectiveness of PARP inhibitors in malignancies: A systematic review (PloS one, 2022) Cochrane review Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis (Expert opinion on drug safety, 2023) Cochrane review Comparison of Adverse Reactions Caused by Olaparib for Different Indications (Frontiers in pharmacology, 2022) Meta-analysis Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis (European journal of clinical pharmacology, 2025) Meta-analysis Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis (Frontiers in immunology, 2024) Meta-analysis Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis (European urology oncology, 2024) Meta-analysis PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology (Breast (Edinburgh, Scotland), 2022) Systematic review Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review (The breast journal, 2024) Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
OXALIPLATIN Repurposing	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 3 Meta-analysis 34 Trial pubs 11 RCT View evidence Registry trials NCT05576077 — A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (TERMINATED) PHASE1 NCT00674206 — A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer (TERMINATED) PHASE2 NCT02077998 — Oxaliplatin in Treating Patients With Metastatic Breast Cancer (COMPLETED) EARLY_PHASE1 NCT07464769 — Compression Therapy of Hands and Feet for the Prevention of Taxane- or Oxaliplatin-induced Peripheral Neuropathy (NOT_YET_RECRUITING) NA NCT03009058 — Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (TERMINATED) PHASE1, PHASE2 NCT03838406 — BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer (COMPLETED) NA NCT01937507 — Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer (TERMINATED) PHASE2 NCT01233505 — Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (TERMINATED) PHASE1 Published literature Cochrane review Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials (British journal of clinical pharmacology, 2014) Cochrane review KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis (Ontario health technology assessment series, 2010) Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors (Cancer medicine, 2026) Meta-analysis Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers (Cancer, 2006) Systematic review Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy (Journal of vascular and interventional radiology : JVIR, 2024) Systematic review Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies-An Update Overview (Molecules (Basel, Switzerland), 2023) Clinical trial publication Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study (Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026) Clinical trial publication Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025) Clinical trial publication Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study) (BMC cancer, 2023) Clinical trial publication An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer (Clinical cancer research : an official journal of the American Association for Cancer Research, 2023) Clinical trial publication A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) (Cancer research and treatment, 2023) Randomized controlled trial A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy (Scientific reports, 2022) CT.gov search · Cochrane · PubMed	DGIdb	—
OXANDROLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETHOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYPHENISATIN ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PACLITAXEL PROTEIN-BOUND Repurposing	Small molecule	Approved	Strong	95	8 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT00019812 — Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 (COMPLETED) PHASE2 NCT00724386 — Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer (COMPLETED) PHASE1 NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (RECRUITING) NA NCT02824575 — Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (TERMINATED) PHASE1 NCT00251472 — A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer (COMPLETED) PHASE2 NCT03873272 — The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL (COMPLETED) NA NCT06190600 — Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy (ACTIVE_NOT_RECRUITING) NA NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 Published literature Systematic review The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review (European journal of cancer (Oxford, England : 1990), 2009) Clinical trial publication FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1 (Clinical cancer research : an official journal of the American Association for Cancer Research, 2020) Clinical trial publication Bioequivalence of paclitaxel protein-bound particles in patients with breast cancer: determining total and unbound paclitaxel in plasma by rapid equilibrium dialysis and liquid chromatography-tandem mass spectrometry (Drug design, development and therapy, 2019) CT.gov search · Cochrane · PubMed	DGIdb	—
PARAMETHASONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PAROXETINE HYDROCHLORIDE, HEMIHYDRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PAZOPANIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PEMBROLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PENTAMIDINE ISETHIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERHEXILINE MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERMETHRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENELZINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENFORMIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PIMOZIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PIPERINE Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study (Phytotherapy research : PTR, 2025) CT.gov search · Cochrane · PubMed	DGIdb	—
PITAVASTATIN CALCIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PODOFILOX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRASTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PREDNICARBATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PREDNISOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PREDNISOLONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PREDNISONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRIMIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROBENECID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROGESTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROMAZINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROMETHAZINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PYRIDOSTIGMINE BROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PYRIMETHAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PYRITHIONE ZINC Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PYRVINIUM PAMOATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
QUERCETIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
QUININE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RABEPRAZOLE SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RALOXIFENE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
REPAGLINIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RESERPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RESVERATROL Repurposing	Small molecule	Approved	Strong	95	3 trials 1 Meta-analysis 4 Trial pubs 3 RCT View evidence Registry trials NCT04266353 — Effect of Resveratrol on Serum IGF2 Among African American Women (WITHDRAWN) NA NCT05306002 — Nutritional Intervention and DNA Damage of Patients With HBOC (COMPLETED) NA NCT03482401 — Disposition of Dietary Polyphenols and Methylxanthines in Mammary Tissues From Breast Cancer Patients (COMPLETED) NA Published literature Meta-analysis Sulforaphane and Epigallocatechin Gallate Restore Estrogen Receptor Expression by Modulating Epigenetic Events in the Breast Cancer Cell Line MDA-MB-231: A Systematic Review and Meta-Analysis (Journal of nutrigenetics and nutrigenomics, 2017) Systematic review The Relationship Between Climate Change and Breast Cancer and Its Management and Preventative Implications in South Africa (International journal of environmental research and public health, 2025) Systematic review Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies-An Update Overview (Molecules (Basel, Switzerland), 2023) Systematic review Endocrine disrupting chemicals and breast cancer: a systematic review of epidemiological studies (Critical reviews in food science and nutrition, 2022) Clinical trial publication Disposition of Dietary Polyphenols in Breast Cancer Patients' Tumors, and Their Associated Anticancer Activity: The Particular Case of Curcumin (Molecular nutrition & food research, 2021) Clinical trial publication Metabolic Profiling of Dietary Polyphenols and Methylxanthines in Normal and Malignant Mammary Tissues from Breast Cancer Patients (Molecular nutrition & food research, 2019) Clinical trial publication A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones (Journal of translational medicine, 2014) Clinical trial publication Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer (Nutrition and cancer, 2012) CT.gov search · Cochrane · PubMed	DGIdb	—
RIBOFLAVIN Repurposing	Small molecule	Approved	Strong	95	2 trials 1 Meta-analysis 9 Trial pubs 7 RCT View evidence Registry trials NCT04669119 — Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy. (UNKNOWN) PHASE4 NCT00204490 — Soy Isoflavones and Breast Cancer Risk Reduction (COMPLETED) PHASE2 Published literature Meta-analysis Association Between One-carbon Metabolism-related Vitamins and Risk of Breast Cancer: A Systematic Review and Meta-analysis of Prospective Studies (Clinical breast cancer, 2020) Clinical trial publication Ticagrelor modestly raises plasma riboflavin concentration in humans and inhibits riboflavin transport by BCRP and MRP4 (Clinical pharmacology and therapeutics, 2024) Clinical trial publication A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants (The Journal of pharmacology and experimental therapeutics, 2024) Clinical trial publication Dietary intake of selected B vitamins in relation to risk of major cancers in women (British journal of cancer, 2008) Clinical trial publication Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy (Vascular pharmacology, 2008) Clinical trial publication Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy (The British journal of nutrition, 2008) CT.gov search · Cochrane · PubMed	DGIdb	—
RIFAMPIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIFAMYCIN SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RIFAPENTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIMONABANT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ROCURONIUM BROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RUCAPARIB Repurposing	Small molecule	Approved	Strong	95	8 trials 1 Cochrane 3 Meta-analysis 5 Trial pubs View evidence Registry trials NCT03911453 — Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors (COMPLETED) EARLY_PHASE1 NCT03542175 — A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy (COMPLETED) PHASE1 NCT00664781 — Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer (COMPLETED) PHASE2 NCT02505048 — A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature (COMPLETED) PHASE2 NCT04171700 — A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes (TERMINATED) PHASE2 NCT03101280 — A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer (COMPLETED) PHASE1 NCT02711137 — Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies (TERMINATED) PHASE1, PHASE2 NCT03992131 — A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (TERMINATED) PHASE1, PHASE2 Published literature Cochrane review Cost-effectiveness of PARP inhibitors in malignancies: A systematic review (PloS one, 2022) Meta-analysis Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis (Journal of chemotherapy (Florence, Italy), 2025) Meta-analysis Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis (European urology oncology, 2024) Meta-analysis Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis (European journal of cancer (Oxford, England : 1990), 2021) Systematic review The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review (International journal of molecular sciences, 2022) Clinical trial publication PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers (British journal of cancer, 2024) Clinical trial publication A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR) (The oncologist, 2024) Clinical trial publication Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation (European journal of cancer (Oxford, England : 1990), 2021) Clinical trial publication Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer (Nature communications, 2020) Clinical trial publication Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer (British journal of cancer, 2016) CT.gov search · Cochrane · PubMed	DGIdb	—
SACITUZUMAB GOVITECAN Repurposing	Small molecule	Approved	Strong	95	8 trials 16 Cochrane 19 Meta-analysis 31 Trial pubs 18 RCT View evidence Registry trials NCT04320693 — Expanded Access for IMMU-132 (APPROVED_FOR_MARKETING) NCT06612203 — Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT07046455 — Trop-2 Targeted PET Probes in Advanced TNBC (RECRUITING) NA NCT05774886 — Implantable Microdevice for TNBC - Pilot Study (WITHDRAWN) PHASE1 NCT06102824 — Organoid-based Functional Precision Therapy for Advanced Breast Cancer (RECRUITING) PHASE2 NCT07582887 — Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response (RECRUITING) NCT05840211 — Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ACTIVE_NOT_RECRUITING) PHASE3 NCT06462092 — Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency: a Bayesian network meta-analysis (BMC cancer, 2026) Cochrane review Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review (BMC cancer, 2026) Cochrane review Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis (Frontiers in pharmacology, 2025) Cochrane review The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data (Frontiers in immunology, 2025) Cochrane review Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis (Frontiers in oncology, 2025) Meta-analysis Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis (European journal of clinical pharmacology, 2026) Meta-analysis Pre-Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta-Analysis and Recommendation (Clinical and translational science, 2026) Systematic review Comparing the Efficacy of Various Treatment Strategies for Patients With Advanced Triple-Negative Breast Cancer: An Umbrella Review (Clinical pharmacology and therapeutics, 2026) Systematic review Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials (Frontiers in immunology, 2025) Clinical trial publication Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer (The New England journal of medicine, 2026) Clinical trial publication Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study (Annals of oncology : official journal of the European Society for Medical Oncology, 2026) Clinical trial publication Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer (The New England journal of medicine, 2025) CT.gov search · Cochrane · PubMed	DGIdb	—
SALMETEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SAQUINAVIR MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SELUMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SERTINDOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SERTRALINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SIMVASTATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SORAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SORAFENIB TOSYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SOTALOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SPARFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SPIRONOLACTONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
STANOZOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SULFACARBAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SULFISOXAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TACROLIMUS ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TALAZOPARIB Repurposing	Small molecule	Approved	Strong	95	8 trials 6 Cochrane 8 Meta-analysis 23 Trial pubs 8 RCT View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT04987931 — Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer (COMPLETED) NCT05141708 — Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m (COMPLETED) NCT03964532 — TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT04703920 — Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer (COMPLETED) PHASE1 NCT05035745 — Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) (RECRUITING) PHASE1, PHASE2 NCT02358200 — Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer (TERMINATED) PHASE1 NCT06735742 — A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer (ACTIVE_NOT_RECRUITING) Published literature Cochrane review Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis (Cancer pathogenesis and therapy, 2024) Cochrane review PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis (Hematology/oncology and stem cell therapy, 2023) Cochrane review Cost-effectiveness of PARP inhibitors in malignancies: A systematic review (PloS one, 2022) Cochrane review Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis (Expert opinion on drug safety, 2023) Cochrane review Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review (PharmacoEconomics, 2022) Meta-analysis Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis (Journal of chemotherapy (Florence, Italy), 2025) Meta-analysis Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis (European urology oncology, 2024) Meta-analysis PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology (Breast (Edinburgh, Scotland), 2022) Meta-analysis Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer (Cancer treatment reviews, 2022) Systematic review Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review (The breast journal, 2024) Clinical trial publication A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer (Cancer, 2026) Clinical trial publication Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion (Proceedings of the National Academy of Sciences of the United States of America, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
TAMOXIFEN CITRATE Repurposing	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 11 Trial pubs 9 RCT View evidence Registry trials NCT02188745 — ER Reactivation Therapy for Breast Cancer (COMPLETED) PHASE2 NCT00032136 — Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer (COMPLETED) PHASE3 NCT01712893 — Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer (COMPLETED) PHASE3 NCT00107263 — Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer (COMPLETED) PHASE3 NCT02517593 — Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake (COMPLETED) PHASE1, PHASE2 NCT02747004 — A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT02936206 — Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. (TERMINATED) PHASE1 NCT00793377 — Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer (COMPLETED) PHASE3 Published literature Cochrane review Drug use evaluation of tamoxifen focusing on off-label use in a managed care population in Israel (Journal of managed care pharmacy : JMCP, 2010) Cochrane review Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer (Annals of internal medicine, 2009) Clinical trial publication [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)] (Gan to kagaku ryoho. Cancer & chemotherapy, 1998) Clinical trial publication Long-term tamoxifen citrate use and potential ocular toxicity (American journal of ophthalmology, 1998) Clinical trial publication Effect of tamoxifen on measurements of hemostasis in healthy women (Archives of internal medicine, 1996) Clinical trial publication Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years (Archives of internal medicine, 1994) Clinical trial publication Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994) Randomized controlled trial Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women (Breast cancer research and treatment, 1994) CT.gov search · Cochrane · PubMed	DGIdb	—
TAMOXIFEN CITRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TAMSULOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TANNIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TELITHROMYCIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TEMOZOLOMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOLACTONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOSTERONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOSTERONE CYPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOSTERONE ENANTHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOSTERONE PROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
THIABENDAZOLE Repurposing	Small molecule	Approved	Strong	95	4 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
THIOCTIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
THIOGUANINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
THIOTEPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIOCONAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLVAPTAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOPOTECAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TOPOTECAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOREMIFENE CITRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRAMETINIB DIMETHYL SULFOXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRASTUZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIAMCINOLONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIAMCINOLONE DIACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRIAMTERENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIBROMSALAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRICLOSAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIFLUOPERAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRILOSTANE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIMETREXATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIPARANOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALPROIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VALRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VANDETANIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VEMURAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VENETOCLAX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VINBLASTINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VINCRISTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VINORELBINE Repurposing	Small molecule	Approved	Strong	95	8 trials 8 Cochrane 10 Meta-analysis 430 Trial pubs 105 RCT View evidence Registry trials NCT03321981 — MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (COMPLETED) PHASE2 NCT00724386 — Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer (COMPLETED) PHASE1 NCT04681911 — Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT00001944 — Vinorelbine and XR9576 to Treat Cancer (COMPLETED) PHASE1 NCT00912275 — Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT02544243 — Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT05856383 — Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (RECRUITING) NCT07556848 — A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer (NOT_YET_RECRUITING) PHASE3 Published literature Cochrane review Metronomic chemotherapy combined with immunotherapy in solid tumor: a systematic review (Translational cancer research, 2026) Cochrane review Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss (Cancers, 2026) Cochrane review Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer (BMC cancer, 2021) Cochrane review Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis (BMC cancer, 2020) Cochrane review Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review  (International journal of clinical pharmacology and therapeutics, 2018) Meta-analysis A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer (Anticancer research, 2019) Meta-analysis Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies (Clinical breast cancer, 2016) Meta-analysis A systematic review of vinorelbine for the treatment of breast cancer (The breast journal, 2013) Systematic review Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review (The Lancet. Oncology, 2011) Clinical trial publication Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study (Annals of oncology : official journal of the European Society for Medical Oncology, 2026) Clinical trial publication Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial (The Lancet. Oncology, 2025) Clinical trial publication Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study (Breast (Edinburgh, Scotland), 2025) CT.gov search · Cochrane · PubMed	DGIdb	—
VINORELBINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VITAMIN A Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VITAMIN K3 Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
WARFARIN POTASSIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ZAFIRLUKAST Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ZIPRASIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ZOLPIDEM TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IDOXIFENE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ACOLBIFENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ADAGLOXAD SIMOLENIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ADEBRELIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AFATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AFATINIB DIMALEATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AFURESERTIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMCENESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMINOGLUTETHIMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMONAFIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ANG1005	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATAMESTANE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATIRMOCICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BALIXAFORTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BALUGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BRIVANIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUPARLISIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUSULFAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CALCIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAMIZESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAMRELIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CARBOPLATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CARMUSTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLODRONIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CULMERCICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CUSTIRSEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYTARABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DALPICICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARBEPOETIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAUNORUBICIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIENESTROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DISITAMAB VEDOTIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFAPROXIRAL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFBEMALENOGRASTIM ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFLAPEGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENCEQUIDAR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN, N-TERMINAL-MGGSHHHHH	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENOBOSARM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENTINOSTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EPIRUBICIN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ESCITALOPRAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETHINYL ESTRADIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETIRINOTECAN PEGOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FAMITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENTANYL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FERRIC CARBOXYMALTOSE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FIBRINOGEN, HUMAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUOROURACIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUZOPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GABAPENTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GEDATOLISIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GIREDESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GONADORELIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GONADORELIN ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GOSERELIN ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEMAY-022	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IBANDRONIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IMLUNESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INAVOLISIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INIPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INTERFERON GAMMA-1B	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IODINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IPATASERTIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IRINOTECAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KN-026	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANREOTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANSOPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LAROTAXEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LASOFOXIFENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LENOGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEROCICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEUCOVORIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LIDOCAINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LOVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MARIMASTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MELPHALAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIFEPRISTONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MILODISTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MITOXANTRONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MITOXANTRONE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MOLGRAMOSTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MORPHINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MOXIFLOXACIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NELIPEPIMUT-S	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NERATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NIRAPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OCTREOTIDE ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OCTREOTIDE PAMOATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OLAPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OXYBUTYNIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PALAZESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PAROXETINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PATRITUMAB DERUXTECAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEGFILGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRIFETRASTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYROTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
QS-21	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RAMUCIRUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REGRAMOSTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RETIFANLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIBOCICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RLY-2608	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB TIRUMOTECAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SARUPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SERPLULIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SULFUR HEXAFLUORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SUNITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SUNITINIB MALATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TARAGARESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TASELISIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TECEMOTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TEGAFUR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TEMSIROLIMUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TESETAXEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TESMILIFENE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIBOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOCILIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TORIPALIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB BOTIDOTIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB DUOCARMAZINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB ENVEDOTIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB MAFODOTIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB PAMIRTECAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB REZETECAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TREBANANIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRETINOIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIPTORELIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TUCIDINOSTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
URACIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VELIPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VENLAFAXINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VEPDEGESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINFLUNINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINORELBINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINORELBINE TARTRATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZANIDATAMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID ANHYDROUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
13-DEOXYDOXORUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
2X-121	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
7-ETHYL-10-HYDROXYCAMPTOTHECIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABEXINOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABIRATERONE ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-751	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADAGRASIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFIMOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFLIBERCEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFP-464	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AGATOLIMOD SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALECTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALEMTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALENDRONIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALISERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALOVUDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALOVUDINE F-18	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALVESPIMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMIFOSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMILORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMINOFLAVONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMRUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTINEOPLASTON A10	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANVATABART OPADOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APATORSEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APATORSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APITOLISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APRICOXIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARSENIC TRIOXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARUNDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARZOXIFENE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AVELUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AXELOPRAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZACITIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-4547	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-9496	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BAVITUXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BAZEDOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BB-1701	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BECATECARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELZUTIFAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMCENTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BENDAMUSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BENMELSTOBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERUBICIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEXAROTENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BI-2536	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BIIB021	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BINIMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMS-690514	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMS-754807	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BORTEZOMIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRIGATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRILANESTRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BROMELAINS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BROSTALLICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRYOSTATIN 1	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BULUMTATUG FUVEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BUPIVACAINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BUPROPION	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
C-1311	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CABOZANTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CADONILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAFELKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAFFEINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMONSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANERTINIB DIHYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANFOSFAMIDE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARVEDILOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CDX-301	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEDIRANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEDIRANIB MALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEMIPLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CERALASERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CERAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CETUXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CFI-400945	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHARCOAL, ACTIVATED	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLOROQUINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CI-1040	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CIMETIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CITALOPRAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CIXUTUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COBIMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COBIMETINIB FUMARATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COLESEVELAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CONTUSUGENE LADENOVEC	Gene therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COPANLISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COPPER	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CP-724714	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CPG-52852	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CR 1447	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CRIZOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CROFELEMER	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CT-7001	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CUSTIRSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
D-MANNOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DACTOLISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DALOTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DANAZOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAROLUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DASATINIB ANHYDROUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DECITABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEFEROXAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DENIFANSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DESMOPRESSIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEUPIRFENIDONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DFP-13318	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DICHLOROACETIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIGOXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DINACICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIPHENHYDRAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIPHENOXYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DISULFIRAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DORDAVIPRONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOSTARLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOVITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXECITINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DROLOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUSIGITUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ECADOTRIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EDOTECARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFTILAGIMOD ALFA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFUNGUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELRAGLUSIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENDOXIFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENILURACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENTRECTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENVAFOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENZALUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENZASTAURIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPALRESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPIGALOCATECHIN GALLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPOTHILONE D	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERFONRILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERLOTINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERTUMAXOMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESOMEPRAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTETROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRAMUSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRAMUSTINE PHOSPHATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETORICOXIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EVEXOMOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EVORPACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EXATECAN MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FAMOTIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEXAGRATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FIGITUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FIRTECAN PEGOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUDARABINE PHOSPHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUOROESTRADIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUVASTATIN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FOLINIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FOLLITROPIN ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FRESOLIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FUTIBATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GALUNISERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANCOTAMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANDOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANETESPIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANITUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEFITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GENISTEIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GIMATECAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GIMERACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GINSENG, AMERICAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GLEMBATUMUMAB VEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GOSSYPOL ACETIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GPI-0100	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GRAPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GTI-2040	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HE3235	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HU3S193	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HUHMFG1	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDRALAZINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROGEN PEROXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROXYPROGESTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICARITIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICRUCUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFINATAMAB DERUXTECAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFOSFAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMETELSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMETELSTAT SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMIQUIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INDISULAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INDOXIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INOSINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-12 HUMAN RECOMBINANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-7	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IPILIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IROFULVEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IROSUSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRX-2	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOFLAVONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISPINESIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IVONESCIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IZALONTAMAB BRENGITECAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KETAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KETOCONAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KETOROLAC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LADIRATUZUMAB VEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LADIRUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LANIQUIDAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAROTRECTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LCL-161	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEMBOREXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENVATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEUCOVORIN CALCIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOBUPIVACAINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIFILEUCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIMANTRAFIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LINIFANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LINSITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LITRONESIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOMUSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LONAFARNIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LONAPRISAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOPERAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOSOXANTRONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUCITANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUNRESERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LURBINECTEDIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUTETIUM OXODOTREOTIDE LU-177	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAGNESIUM SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MARACICLATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MERCAPTOPURINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MESNA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METFORMIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHIONINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MILADEMETAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MIRDAMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MIROSTIPEN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-2206	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MM-111	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MODAFINIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MONALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MOTESANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEBIVOLOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEDAPLATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NILOTINIB HYDROCHLORIDE MONOHYDRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIMOTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NINTEDANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIRAPARIB TOSYLATE MONOHYDRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIROGACESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NITROGLYCERIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OCIPERLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ODANACATIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLECLUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLINVACIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ONAPRISTONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ONARTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OPEVESOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OPRELVEKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORTATAXEL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORTERONEL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OSIMERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OSUGACESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OTERACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXALIPLATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PACLITAXEL POLIGLUMEX	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PACMILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALIFOSFAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAMIDRONIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAMIPARIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PANITUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PANOBINOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PATUPILONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAXALISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAZOPANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAZOPANIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PELAREOREP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMETREXED	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMETREXED DISODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMIGATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMRAMETOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PENPULIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PERFLUTREN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PERIFOSINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PERILLYL ALCOHOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-04691502	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PHENYLACETIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PICTILISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIFUSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIPENDOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PITAVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIXANTRONE DIMALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLATINUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PONATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POZIOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PRALSETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PRALUZATAMAB RAVTANSINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREGABALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREXASERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROPRANOLOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PUCOTENLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PYRAZOLOACRIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RACEMETYROSINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RACOTUMOMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RADIUM RA 223 DICHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RALIMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RALOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RANITIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REBIMASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REGORAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REPARIXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RETASPIMYCIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RETLIRAFUSP ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REZVILUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RG-4733	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RHIZOXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIDAFOROLIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIFAXIMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RISEDRONATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROGARATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROMIDEPSIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROMIPLOSTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUBITECAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUCAPARIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
S1?	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SABIZABULIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAGOPILONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAMOTOLISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAPACITABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAPANISERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAPITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAR-566658	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SARACATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SATRAPLATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELPERCATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELUMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEPANTRONIUM BROMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERABELISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERIBANTUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEVITERONEL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEVOFLURANE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILYMARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SINTILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SITRAVATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SONIDEGIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SONTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SORAFENIB TOSYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOTORASIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SU-014813	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SULFORAPHANE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SULINDAC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SURUFATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TALIMOGENE LAHERPAREPVEC	Gene therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TANESPIMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TARIQUIDAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAS-108	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TASISULAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAVOKINOGENE TELSEPLASMID	Gene therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEGTOCICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELAGLENASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELAPRISTONE ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMOZOLOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TENALISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEPOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEPROTUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESMILIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TETRAHYDROURIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIGATUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TINENGOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIOMOLIBDATE CHOLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIOMOLIBDATE DIAMMONIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIPIFARNIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIPIRACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIVANTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIVOZANIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOCOTRIENOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOMIVOSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOPOTECAN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRABECTEDIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRAMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB IMBOTOLIMOD	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB VEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREMELIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIAPINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIFLURIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRILACICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIPTORELIN PAMOATE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TROCULEUCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TUSAMITAMAB RAVTANSINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UPAMOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UPROSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
URSODIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UTOMILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALACYCLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALGANCICLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALPROIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALSPODAR	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VANDETANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARLITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VATALANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VELEDIMEX	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VELIGROTUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEMURAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VENETOCLAX	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VINBLASTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VISMODEGIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VISTUSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VORINOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
XENTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZELENECTIDE PEVEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZENOCUTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZEPRUMETOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZIBOTENTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZIMBERELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZONGERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZOPTARELIN DOXORUBICIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZOTATIFIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK126 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
.ALPHA.-TOCOPHERYLOXYACETIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACTINIUM AC 225 DOTATATE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ADERBASIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ADG-106	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AFELETECAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AK-01	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALDOXORUBICIN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALEXTATUG	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALITRETINOIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALMURTIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALOBRESIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALVOCIDIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AMXT-1501 DICAPRATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANDECALIXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANETUMAB RAVTANSINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANPOCOGIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
APROTININ	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
APRUTUMAB IXADOTIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ARTESUNATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AS-1403	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASCIMINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASP-1948	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASTX-660	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ATAMPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AVUTOMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AXATILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AXITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-5363	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-8186	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-8835	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-9574	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZENOSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BASILIXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BCG LIVE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BCG VACCINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BELINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BEMPEGALDESLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BERZOSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BEXMARILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BGT-226	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIMIRALISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BINTRAFUSP ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIRABRESIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIVATUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-986299	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-986310	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
C-188-9	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CABERGOLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CALCIFEDIOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAMPTOTHECIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAPMATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CARFILZOMIB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAROTUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CDX-1140	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CEDAZURIDINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CINREBAFUSP ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CIRMTUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
COM-701	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
COPANLISIB HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CUDC-101	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CX-5461	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYC-065	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DACLIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DARATUMUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DELTA-8-TETRAHYDROCANNABINOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DENILEUKIN DIFTITOX	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DF-1001	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DHES-0815A	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DIAZEPINOMICIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DOTMP SM-153	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
E-7090	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
E-7766	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EBVACICLIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFINEPTAKIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFLORNITHINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFLORNITHINE HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EGANELISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ELACESTRANT HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ELGEMTUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMVODODSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ENFORTUMAB VEDOTIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EPOFOLATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERDAFITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESTROGEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EXISULIND	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
F16IL2	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FAPI GA-68	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERRIC OXYHYDROXIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERROUS SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FGFR INHIBITOR DEBIO 1347	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOXY-5	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FRUQUINTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALINPEPIMUT-S	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALLIUM GA 68 GOZETOTIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GATIPOTUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GDC-0927	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GEBASAXTUREV	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM BROMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-1059615	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
H3B-6545	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HILTONOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYALURONIDASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IBRUTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ICOSAPENT ETHYL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IDASANUTLIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IDRONOXIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMC-CS4	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMEXON	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMMUNOCYTOKINE NHS-IL12	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INCOMPLETE FREUND'S ADJUVANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INDIBULIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INFIGRATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INFLUENZA A VIRUS, SPLIT VIRION	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INFLUENZA VIRUS VACCINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INOBRODIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INX-315	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IRON ISOMALTOSIDE 1000	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IRX-4204	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ISMIDENON	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ITRACONAZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IXAZOMIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IZELTABART TAPATANSINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
KW-2450	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LANERKITUG	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LAPACHONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LB-100	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LEFLUNOMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LINOLEIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LMB-9	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LSZ-102	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUMINESPIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUMRETUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU 177 ZADAVOTIDE GURAXETAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU177 EDOTREOTIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUVIXASERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LY-2090314	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LY-2780301	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
M4344	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAGROLIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAVEROPEPIMUT-S	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAVORIXAFOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MBQ-167	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MCS-110	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ME-344	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEDI-4276	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEDI-6469	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MELK INHIBITOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MERESTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MINOXIDIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MIRVETUXIMAB SORAVTANSINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MIRZOTAMAB CLEZUTOCLAX	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MITAZALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-0752	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ML-246	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MOLIBRESIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MTI-31	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MUBRITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MUPLESTIM	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NABIXIMOLS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAVITOCLAX	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAXITAMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAXTARUBICIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NEROFE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NIDANILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NITROGEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NOGAPENDEKIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OB-002	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OBEROTATUG RAVTANSINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OBINUTUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OBLIMERSEN SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ODETIGLUCAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OMEGA-3-ACID ETHYL ESTERS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONALESPIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONVANSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
P-276-00	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PACRITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PARICALCITOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PARSACLISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PATRITUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGARGIMINASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGVORHYALURONIDASE ALFA	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEMVIDUTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEPINEMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEXIDARTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PHENELZINE SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PILARALISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PKI-179	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PRASTERONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PRUXELUTAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PU-H71	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
QUERCETIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
QUINAZOLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RAD-140	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REBASTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REFAMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RICOLINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RILUZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RIMIDUCID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RINATABART SESUTECAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RINTATOLIMOD	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RINTODESTRANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RISOVALISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RITONAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RUNIMOTAMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RUPITASERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SAMARIUM SM-153	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SELICICLIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SELICRELUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SELINEXOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SENAPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SENEXIN B	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SEPHB4-HSA	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SNX 5422	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SODIUM IODIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SPARTALIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
STX-478	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SULANEMADLIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SURAMIN HEXASODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SURATADENOTUREV	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SY-5609	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TAS-116	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TENATUMOMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TESEVATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE PROPIONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TILARGININE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIRBANIBULIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIVOZANIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TOMUZOTUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRICIRIBINE PHOSPHATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRIS(8-HYDROXYQUINOLINATO)GALLIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRODUSQUEMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TROTABRESIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRYPTOPHAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TTC-352	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TUVUSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TUXOBERTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
UAB-30	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
UCN-01	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VACTOSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VALEMETOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VANTICTUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VARENICLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VARLILUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VELDOREOTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VERTEPORFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VEVOCTADEKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VITAMIN B12	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOBRAMITAMAB DUOCARMAZINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOLAGIDEMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOXTALISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VUDALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VUSOLIMOGENE ODERPAREPVEC	Gene therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
WAX, EMULSIFYING	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
YTTRIUM Y-90	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZB-716	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZELENIRSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZEN-3694	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZUNSEMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
(R)-PFI-2	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ABEMACICLIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALPELISIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANASTROZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANATUMOMAB MAFENATOX	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ARCITUMOMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ARZOXIFENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIX 01294 TRIHYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BLEOMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BOSUTINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CABAZITAXEL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CAPECITABINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CAPIVASERTIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLODRONATE DISODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CMB-401	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CROCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DATELLIPTIUM CHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DATOPOTAMAB DERUXTECAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEMECLOCYCLINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DENOSUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXRAZOXANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXRAZOXANE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOCETAXEL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DROMOSTANOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DROSPIRENONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DYDROGESTERONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ELACESTRANT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ENALAPRIL MALEATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ERIBULIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ERIBULIN MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESKETAMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESTROGENS, CONJUGATED	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESTROGENS, ESTERIFIED	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EVEROLIMUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EXEMESTANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FADROZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUOROESTRADIOL F-18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUOXYMESTERONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FORMESTANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FULVESTRANT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GARLIC	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GEMCITABINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GESTRINONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GOSERELIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IBANDRONATE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INDIUM IN 111 SATUMOMAB PENDETIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IODIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IXABEPILONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAPATINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAPATINIB DITOSYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LETROZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE ACETATE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVORMELOXIFENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LOBAPLATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MARGETUXIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MEGESTROL ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MERIMEPODIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHOTREXATE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLSELENOCYSTEINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLTESTOSTERONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MIDAZOLAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MITOMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NEFOPAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NERATINIB MALEATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NOMEGESTROL ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NOMIFENSINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NORETHINDRONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLSALAZINE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ONDANSETRON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OXIDIZED GLUTATHIONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OXYCODONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PACLITAXEL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PALBOCICLIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PAMIDRONATE DISODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PEPLOMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PERTUZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIRARUBICIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PRALATREXATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PYRROLIDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUINESTROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RALOXIFENE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
REMIFENTANIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
REMIMAZOLAM BESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIBOCICLIB SUCCINATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIVOCERANIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIVOCERANIB MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROGLETIMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROPIVACAINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB GOVITECAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SACUBITRIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TALAPORFIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TALAZOPARIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TALAZOPARIB TOSYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAMOXIFEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAMOXIFEN CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TECHNETIUM TC 99M SULFUR COLLOID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TECHNETIUM TC 99M TETROFOSMIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TECHNETIUM TC 99M TILMANOCEPT	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOXICAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TESTOLACTONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TETRACYCLINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THIOTEPA	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOREMIFENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOREMIFENE CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOZINAMERAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRANEXAMIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB DERUXTECAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB EMTANSINE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TUCATINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VALSARTAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VITAMIN E	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINDOXIFENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACOLBIFENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ADAGLOXAD SIMOLENIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ADEBRELIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AFATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AFATINIB DIMALEATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AFURESERTIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMCENESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMINOGLUTETHIMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMONAFIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ANG1005	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATAMESTANE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATIRMOCICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BALIXAFORTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BALUGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BICALUTAMIDE	Small molecule	Phase III	Moderate	80	8 trials 3 Trial pubs View evidence Registry trials NCT02605486 — Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT05095207 — Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer (RECRUITING) PHASE1, PHASE2 NCT06365788 — Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer (RECRUITING) PHASE2 NCT03650894 — Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (ACTIVE_NOT_RECRUITING) PHASE2 NCT00590213 — Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX (COMPLETED) PHASE4 NCT00468715 — Bicalutamide in Treating Patients With Metastatic Breast Cancer (COMPLETED) PHASE2 NCT06727357 — Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP (ACTIVE_NOT_RECRUITING) PHASE2 NCT03055312 — Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer (TERMINATED) PHASE3 Published literature Clinical trial publication Serial [(18)F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer (European journal of cancer (Oxford, England : 1990), 2021) Clinical trial publication Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer (The oncologist, 2020) Clinical trial publication Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer (Clinical cancer research : an official journal of the American Association for Cancer Research, 2013) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
BRIVANIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUPARLISIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUSULFAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CALCIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAMIZESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAMRELIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CARBOPLATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CARMUSTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLODRONIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CULMERCICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CUSTIRSEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYTARABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DALPICICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARBEPOETIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DAUNORUBICIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIENESTROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DISITAMAB VEDOTIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFAPROXIRAL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFBEMALENOGRASTIM ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFLAPEGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENCEQUIDAR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN, N-TERMINAL-MGGSHHHHH	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENOBOSARM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ENTINOSTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EPIRUBICIN	Small molecule	Phase III	Moderate	80	8 trials 11 Cochrane 21 Meta-analysis 975 Trial pubs 561 RCT View evidence Registry trials NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT02115152 — Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer (UNKNOWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 NCT05909332 — Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) (RECRUITING) PHASE3 NCT01996267 — Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (ACTIVE_NOT_RECRUITING) PHASE3 NCT00003012 — Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer (COMPLETED) PHASE3 NCT01159236 — Molecular Triaging of Newly Diagnosed Breast Cancer (WITHDRAWN) NA Published literature Cochrane review Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials (Cardio-oncology (London, England), 2025) Cochrane review Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis (BMC women's health, 2025) Cochrane review The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis (Current oncology (Toronto, Ont.), 2024) Cochrane review Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis (Cancer medicine, 2024) Cochrane review Effects of Integrated Chinese Traditional Medicine and Conventional Western Medicine on the Quality of Life of Breast Cancer Patients: A Systematic Review and Meta-Analysis (Evidence-based complementary and alternative medicine : eCAM, 2022) Meta-analysis Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer (World journal of surgical oncology, 2021) Meta-analysis Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021) Systematic review [Effect of taste perception on nutritional status in patients with breast cancer: a systematic review] (Nutricion hospitalaria, 2025) Clinical trial publication Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA) (JCO global oncology, 2026) Clinical trial publication Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Clinical trial publication Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (Annals of surgical oncology, 2026) Clinical trial publication Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial (BMJ (Clinical research ed.), 2025) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
EPIRUBICIN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ESCITALOPRAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETHINYL ESTRADIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETIRINOTECAN PEGOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FAMITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENTANYL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FERRIC CARBOXYMALTOSE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FIBRINOGEN, HUMAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUOROURACIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUZOPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GABAPENTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GEDATOLISIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GIREDESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GONADORELIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GONADORELIN ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GOSERELIN ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HEMAY-022	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IBANDRONIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IDOXIFENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IMLUNESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INAVOLISIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INIPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INTERFERON GAMMA-1B	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IODINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IPATASERTIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IRINOTECAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KN-026	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANREOTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANSOPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LAROTAXEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LASOFOXIFENE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LENOGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEROCICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEUCOVORIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LIDOCAINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LOVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MARIMASTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MELPHALAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MIFEPRISTONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MILODISTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MITOXANTRONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MITOXANTRONE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MOLGRAMOSTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MORPHINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MOXIFLOXACIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NELIPEPIMUT-S	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NERATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NIRAPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OCTREOTIDE ACETATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OCTREOTIDE PAMOATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OLAPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OXYBUTYNIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PALAZESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PAROXETINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PATRITUMAB DERUXTECAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEGFILGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRIFETRASTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PYROTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
QS-21	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RAMUCIRUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
REGRAMOSTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RETIFANLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIBOCICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RLY-2608	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB TIRUMOTECAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SARUPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SERPLULIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIROLIMUS	Small molecule	Phase III	Moderate	80	8 trials 2 Trial pubs View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT03805399 — FUSCC Refractory TNBC Umbrella (FUTURE) (UNKNOWN) PHASE1, PHASE2 NCT02520063 — Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT01088893 — Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy (UNKNOWN) PHASE2 NCT03659136 — The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread (COMPLETED) PHASE2 NCT05983107 — Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (RECRUITING) PHASE2 NCT01111825 — Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT02809404 — Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) (COMPLETED) Published literature Systematic review mTOR inhibitors in breast cancer: a systematic review (Gynecologic oncology, 2012) Clinical trial publication Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy (Breast cancer research and treatment, 2015) Clinical trial publication Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer (Investigational new drugs, 2010) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SULFUR HEXAFLUORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SUNITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SUNITINIB MALATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TARAGARESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TASELISIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TECEMOTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TEGAFUR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TEMSIROLIMUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TESETAXEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TESMILIFENE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIBOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOCILIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TORIPALIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB BOTIDOTIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB DUOCARMAZINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB ENVEDOTIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB MAFODOTIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB PAMIRTECAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB REZETECAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TREBANANIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRETINOIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIPTORELIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TUCIDINOSTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
URACIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VELIPARIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VENLAFAXINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VEPDEGESTRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINFLUNINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINORELBINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINORELBINE TARTRATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZANIDATAMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID ANHYDROUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
13-DEOXYDOXORUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
2X-121	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
7-ETHYL-10-HYDROXYCAMPTOTHECIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABEXINOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABIRATERONE ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-751	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADAGRASIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFIMOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFLIBERCEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFP-464	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AGATOLIMOD SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALECTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALEMTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALENDRONIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALISERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALOVUDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALOVUDINE F-18	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALVESPIMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMIFOSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMILORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMINOFLAVONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMRUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTINEOPLASTON A10	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANVATABART OPADOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APATORSEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APATORSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APITOLISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APRICOXIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARSENIC TRIOXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARUNDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARZOXIFENE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AVELUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AXELOPRAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZACITIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-4547	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-9496	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BAVITUXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BAZEDOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BB-1701	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BECATECARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELZUTIFAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMCENTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BENDAMUSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BENMELSTOBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERUBICIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEXAROTENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BI-2536	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BIIB021	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BINIMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMS-690514	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMS-754807	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BORTEZOMIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRIGATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRILANESTRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BROMELAINS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BROSTALLICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRYOSTATIN 1	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BULUMTATUG FUVEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BUPIVACAINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BUPROPION	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
C-1311	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CABOZANTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CADONILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAFELKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAFFEINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMONSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANERTINIB DIHYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANFOSFAMIDE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARVEDILOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CDX-301	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEDIRANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEDIRANIB MALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEMIPLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CERALASERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CERAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CETUXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CFI-400945	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHARCOAL, ACTIVATED	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHLOROQUINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CI-1040	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CIMETIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CITALOPRAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CIXUTUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COBIMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COBIMETINIB FUMARATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COLESEVELAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CONTUSUGENE LADENOVEC	Gene therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COPANLISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COPPER	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CP-724714	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CPG-52852	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CR 1447	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CRIZOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CROFELEMER	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CT-7001	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CUSTIRSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
D-MANNOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DACTOLISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DALOTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DANAZOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DAROLUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DASATINIB ANHYDROUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DECITABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEFEROXAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DENIFANSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DESMOPRESSIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEUPIRFENIDONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DFP-13318	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DICHLOROACETIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIGOXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DINACICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIPHENHYDRAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIPHENOXYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DISULFIRAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DORDAVIPRONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOSTARLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOVITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXECITINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DROLOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUSIGITUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ECADOTRIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EDOTECARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFTILAGIMOD ALFA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFUNGUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELRAGLUSIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENDOXIFEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENILURACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENTRECTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENVAFOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENZALUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENZASTAURIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPALRESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPIGALOCATECHIN GALLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EPOTHILONE D	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERFONRILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERLOTINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ERTUMAXOMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESOMEPRAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTETROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRAMUSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRAMUSTINE PHOSPHATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESTRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETORICOXIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EVEXOMOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EVORPACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EXATECAN MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FAMOTIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEXAGRATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FIGITUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FIRTECAN PEGOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUDARABINE PHOSPHATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUOROESTRADIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUVASTATIN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FOLINIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FOLLITROPIN ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FRESOLIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FUTIBATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GALUNISERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANCOTAMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANDOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANETESPIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GANITUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEFITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GENISTEIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GIMATECAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GIMERACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GINSENG, AMERICAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GLEMBATUMUMAB VEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GOSSYPOL ACETIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GPI-0100	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GRAPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GTI-2040	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HE3235	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HU3S193	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HUHMFG1	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDRALAZINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROGEN PEROXIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROXYPROGESTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICARITIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICRUCUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFINATAMAB DERUXTECAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFOSFAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMETELSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMETELSTAT SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMIQUIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INDISULAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INDOXIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INOSINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-12 HUMAN RECOMBINANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-7	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IPILIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IROFULVEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IROSUSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRX-2	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOFLAVONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISPINESIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IVONESCIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IZALONTAMAB BRENGITECAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KETAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KETOCONAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KETOROLAC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LADIRATUZUMAB VEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LADIRUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LANIQUIDAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAROTRECTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LCL-161	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEMBOREXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENVATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEUCOVORIN CALCIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOBUPIVACAINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIFILEUCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIMANTRAFIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LINIFANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LINSITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LITRONESIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOMUSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LONAFARNIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LONAPRISAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOPERAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOSOXANTRONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUCITANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUNRESERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LURBINECTEDIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUTETIUM OXODOTREOTIDE LU-177	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAGNESIUM SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MARACICLATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MERCAPTOPURINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MESNA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METFORMIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHIONINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MILADEMETAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MIRDAMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MIROSTIPEN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-2206	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MM-111	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MODAFINIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MONALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MOTESANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEBIVOLOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEDAPLATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NILOTINIB HYDROCHLORIDE MONOHYDRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIMOTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NINTEDANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIRAPARIB TOSYLATE MONOHYDRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIROGACESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NITROGLYCERIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OCIPERLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ODANACATIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLECLUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLINVACIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ONAPRISTONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ONARTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OPEVESOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OPRELVEKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORTATAXEL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORTERONEL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OSIMERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OSUGACESTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OTERACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXALIPLATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PACLITAXEL POLIGLUMEX	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PACMILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALIFOSFAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAMIDRONIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAMIPARIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PANITUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PANOBINOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PATUPILONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAXALISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAZOPANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAZOPANIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PELAREOREP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMETREXED	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMETREXED DISODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMIGATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMRAMETOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PENPULIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PERFLUTREN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PERIFOSINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PERILLYL ALCOHOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-04691502	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PHENYLACETIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PICTILISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIFUSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIPENDOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PITAVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIXANTRONE DIMALEATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLATINUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PONATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POZIOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PRALSETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PRALUZATAMAB RAVTANSINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREGABALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREXASERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROPRANOLOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PUCOTENLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PYRAZOLOACRIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RACEMETYROSINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RACOTUMOMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RADIUM RA 223 DICHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RALIMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RALOXIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RANITIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REBIMASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REGORAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REPARIXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RETASPIMYCIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RETLIRAFUSP ALFA	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REZVILUTAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RG-4733	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RHIZOXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIDAFOROLIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RIFAXIMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RISEDRONATE SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROGARATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROMIDEPSIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROMIPLOSTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUBITECAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUCAPARIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
S1?	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SABIZABULIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAGOPILONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAMOTOLISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAPACITABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAPANISERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAPITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAR-566658	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SARACATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SATRAPLATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELPERCATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELUMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEPANTRONIUM BROMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERABELISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERIBANTUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEVITERONEL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SEVOFLURANE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILYMARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SINTILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SITRAVATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SONIDEGIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SONTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SORAFENIB TOSYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOTORASIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SU-014813	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SULFORAPHANE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SULINDAC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SURUFATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TALIMOGENE LAHERPAREPVEC	Gene therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TANESPIMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TARIQUIDAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAS-108	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TASISULAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAVOKINOGENE TELSEPLASMID	Gene therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEGTOCICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELAGLENASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELAPRISTONE ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMOZOLOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TENALISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEPOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEPROTUMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESMILIFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TETRAHYDROURIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIGATUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TINENGOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIOMOLIBDATE CHOLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIOMOLIBDATE DIAMMONIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIPIFARNIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIPIRACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIVANTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIVOZANIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOCOTRIENOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOMIVOSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOPOTECAN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRABECTEDIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRAMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB IMBOTOLIMOD	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB VEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREMELIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIAPINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIFLURIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRILACICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIPTORELIN PAMOATE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TROCULEUCEL	Cell therapy	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TUSAMITAMAB RAVTANSINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UPAMOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UPROSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
URSODIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UTOMILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALACYCLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALGANCICLOVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALPROIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALSPODAR	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VANDETANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARLITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VATALANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VELEDIMEX	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VELIGROTUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEMURAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VENETOCLAX	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VINBLASTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VISMODEGIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VISTUSERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VORINOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
XENTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZELENECTIDE PEVEDOTIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZENOCUTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZEPRUMETOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZIBOTENTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZIMBERELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZONGERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZOPTARELIN DOXORUBICIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZOTATIFIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
cis-Diammineplatinum (II) complex	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
.ALPHA.-TOCOPHERYLOXYACETIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACTINIUM AC 225 DOTATATE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ADERBASIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ADG-106	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AFELETECAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AK-01	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALDOXORUBICIN HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALEXTATUG	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALITRETINOIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALMURTIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALOBRESIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALVOCIDIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AMXT-1501 DICAPRATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANDECALIXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANETUMAB RAVTANSINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANPOCOGIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
APROTININ	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
APRUTUMAB IXADOTIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ARTESUNATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AS-1403	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASCIMINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASP-1948	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ASTX-660	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ATAMPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AVUTOMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AXATILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AXITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-5363	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-8186	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-8835	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-9574	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZENOSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BASILIXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BCG LIVE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BCG VACCINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BELINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BEMPEGALDESLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BERZOSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BEXMARILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BGT-226	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIMIRALISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BINTRAFUSP ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIRABRESIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIVATUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-986299	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-986310	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
C-188-9	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CABERGOLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CALCIFEDIOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAMPTOTHECIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAPMATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CARFILZOMIB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAROTUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CDX-1140	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CEDAZURIDINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CINREBAFUSP ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CIRMTUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
COM-701	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
COPANLISIB HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CUDC-101	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CX-5461	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYC-065	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DACLIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DARATUMUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DELTA-8-TETRAHYDROCANNABINOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DENILEUKIN DIFTITOX	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DF-1001	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DHES-0815A	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DIAZEPINOMICIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DOTMP SM-153	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
E-7090	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
E-7766	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EBVACICLIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFINEPTAKIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFLORNITHINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EFLORNITHINE HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EGANELISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ELACESTRANT HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ELGEMTUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EMVODODSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ENFORTUMAB VEDOTIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EPOFOLATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERDAFITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESTROGEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EXISULIND	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
F16IL2	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FAPI GA-68	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERRIC OXYHYDROXIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERROUS SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FGFR INHIBITOR DEBIO 1347	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOLIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FOXY-5	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FRUQUINTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALINPEPIMUT-S	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALLIUM GA 68 GOZETOTIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GATIPOTUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GDC-0927	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GEBASAXTUREV	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM BROMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-1059615	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
H3B-6545	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HILTONOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYALURONIDASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IBRUTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ICOSAPENT ETHYL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IDASANUTLIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IDRONOXIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMC-CS4	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMEXON	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMMUNOCYTOKINE NHS-IL12	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INCOMPLETE FREUND'S ADJUVANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INDIBULIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INFIGRATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INFLUENZA A VIRUS, SPLIT VIRION	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INFLUENZA VIRUS VACCINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INOBRODIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INX-315	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IRON ISOMALTOSIDE 1000	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IRX-4204	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ISMIDENON	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ITRACONAZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IXAZOMIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IZELTABART TAPATANSINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
KW-2450	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LANERKITUG	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LAPACHONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LB-100	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LEFLUNOMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LINOLEIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LMB-9	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LSZ-102	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUMINESPIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUMRETUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU 177 ZADAVOTIDE GURAXETAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUTETIUM LU177 EDOTREOTIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LUVIXASERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LY-2090314	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LY-2780301	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
M4344	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAGROLIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAVEROPEPIMUT-S	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAVORIXAFOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MBQ-167	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MCS-110	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ME-344	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEDI-4276	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEDI-6469	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MELK INHIBITOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MERESTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHOXSALEN	Small molecule	Phase I	Emerging	35	2 trials View evidence Registry trials NCT04389281 — X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (RECRUITING) PHASE1 NCT04720664 — Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
MINOXIDIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MIRVETUXIMAB SORAVTANSINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MIRZOTAMAB CLEZUTOCLAX	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MITAZALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-0752	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ML-246	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MOLIBRESIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MTI-31	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MUBRITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MUPLESTIM	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NABIXIMOLS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAVITOCLAX	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAXITAMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAXTARUBICIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NEROFE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NIDANILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NITROGEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NOGAPENDEKIN ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OB-002	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OBEROTATUG RAVTANSINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OBINUTUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OBLIMERSEN SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ODETIGLUCAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OMEGA-3 FATTY ACIDS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OMEGA-3-ACID ETHYL ESTERS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONALESPIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONVANSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
P-276-00	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PACRITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PARICALCITOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PARSACLISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PATRITUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGARGIMINASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGVORHYALURONIDASE ALFA	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEMVIDUTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEPINEMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEXIDARTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PHENELZINE SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PILARALISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PKI-179	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PRASTERONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PRUXELUTAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PU-H71	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
QUERCETIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
QUINAZOLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RAD-140	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REBASTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REFAMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RICOLINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RILUZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RIMIDUCID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RINATABART SESUTECAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RINTATOLIMOD	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RINTODESTRANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RISOVALISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RITONAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RUNIMOTAMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RUPITASERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SAMARIUM SM-153	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SELICICLIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SELICRELUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SELINEXOR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SENAPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SENEXIN B	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SEPHB4-HSA	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SNX 5422	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SODIUM IODIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SPARTALIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
STX-478	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SULANEMADLIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SURAMIN HEXASODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SURATADENOTUREV	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SY-5609	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TAS-116	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TENATUMOMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TESEVATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE PROPIONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TILARGININE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIRBANIBULIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIVOZANIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TOMUZOTUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRICIRIBINE PHOSPHATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRIS(8-HYDROXYQUINOLINATO)GALLIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRODUSQUEMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TROTABRESIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TRYPTOPHAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TTC-352	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TUVUSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TUXOBERTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
UAB-30	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
UCN-01	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VACTOSERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VALEMETOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VANTICTUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VARENICLINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VARLILUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VELDOREOTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VERTEPORFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VEVOCTADEKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VITAMIN B12	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOBRAMITAMAB DUOCARMAZINE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOLAGIDEMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOXTALISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VUDALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VUSOLIMOGENE ODERPAREPVEC	Gene therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
WAX, EMULSIFYING	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
YTTRIUM Y-90	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZB-716	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZELENIRSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZEN-3694	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZUNSEMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
(R)-PFI-2	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ABEMACICLIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALPELISIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANASTROZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANATUMOMAB MAFENATOX	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ARCITUMOMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ARZOXIFENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BIX 01294 TRIHYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BLEOMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BOSUTINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CABAZITAXEL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CAPECITABINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CAPIVASERTIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLODRONATE DISODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CMB-401	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CROCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DATELLIPTIUM CHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DATOPOTAMAB DERUXTECAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEMECLOCYCLINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DENOSUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXRAZOXANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXRAZOXANE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOCETAXEL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DROMOSTANOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DROSPIRENONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DYDROGESTERONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ELACESTRANT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ENALAPRIL MALEATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ERIBULIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ERIBULIN MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESKETAMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESTROGENS, CONJUGATED	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESTROGENS, ESTERIFIED	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EVEROLIMUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EXEMESTANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FADROZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUMAZENIL	Small molecule	Preclinical	Emerging	15	1 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT05435911 — Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol (COMPLETED) NA Published literature Clinical trial publication Effects of remimazolam vs. an etomidate-propofol mixture on postoperative cognitive function in elderly female patients undergoing radical mastectomy for breast cancer: a randomized controlled trial (Frontiers in medicine, 2025) Clinical trial publication Comparison of recovery profiles between total intravenous anaesthesia with propofol or remimazolam reversed with flumazenil in patients undergoing breast surgery: A randomised controlled trial (European journal of anaesthesiology, 2024) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
FLUOROESTRADIOL F-18	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUOXYMESTERONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FORMESTANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FULVESTRANT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GARLIC	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GEMCITABINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GESTRINONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GOSERELIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IBANDRONATE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INDIUM IN 111 SATUMOMAB PENDETIDE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IODIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IXABEPILONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAPATINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAPATINIB DITOSYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LETROZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE ACETATE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVORMELOXIFENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LOBAPLATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MARGETUXIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MEGESTROL ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MERIMEPODIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHOTREXATE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLSELENOCYSTEINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLTESTOSTERONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MIDAZOLAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MITOMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NEFOPAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NERATINIB MALEATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NOMEGESTROL ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NOMIFENSINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NORETHINDRONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLSALAZINE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ONDANSETRON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OXIDIZED GLUTATHIONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OXYCODONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PACLITAXEL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PALBOCICLIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PAMIDRONATE DISODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PEPLOMYCIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PERTUZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIRARUBICIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PRALATREXATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PYRROLIDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUINESTROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RALOXIFENE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
REMIFENTANIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
REMIMAZOLAM BESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIBOCICLIB SUCCINATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIVOCERANIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIVOCERANIB MESYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROGLETIMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ROPIVACAINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB GOVITECAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SACUBITRIL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TALAPORFIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TALAZOPARIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TALAZOPARIB TOSYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAMOXIFEN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAMOXIFEN CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TECHNETIUM TC 99M SULFUR COLLOID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TECHNETIUM TC 99M TETROFOSMIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TECHNETIUM TC 99M TILMANOCEPT	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOXICAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TESTOLACTONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TETRACYCLINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THIOTEPA	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOREMIFENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOREMIFENE CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOZINAMERAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRANEXAMIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB DERUXTECAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB EMTANSINE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TUCATINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VALSARTAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VITAMIN E	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINDOXIFENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APIGENIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ASTEMIZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
ATRACURIUM BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BENORILATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BEXAROTENE Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	8 trials 3 Trial pubs View evidence Registry trials NCT02605486 — Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT05095207 — Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer (RECRUITING) PHASE1, PHASE2 NCT06365788 — Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer (RECRUITING) PHASE2 NCT03650894 — Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (ACTIVE_NOT_RECRUITING) PHASE2 NCT00590213 — Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX (COMPLETED) PHASE4 NCT00468715 — Bicalutamide in Treating Patients With Metastatic Breast Cancer (COMPLETED) PHASE2 NCT06727357 — Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP (ACTIVE_NOT_RECRUITING) PHASE2 NCT03055312 — Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer (TERMINATED) PHASE3 Published literature Clinical trial publication Serial [(18)F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer (European journal of cancer (Oxford, England : 1990), 2021) Clinical trial publication Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer (The oncologist, 2020) Clinical trial publication Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer (Clinical cancer research : an official journal of the American Association for Cancer Research, 2013) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BINIMETINIB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BISACODYL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BLEOMYCIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	—	DGIdb	—
BORTEZOMIB Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing via BRCA2	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUPRENORPHINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUTAMBEN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CAFFEINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCIFEDIOL ANHYDROUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCIPOTRIENE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCITRIOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CANRENONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPIVASERTIB Repurposing via AKT2	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 24 Cochrane 30 Meta-analysis 416 Trial pubs 172 RCT View evidence Registry trials NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (RECRUITING) NA NCT06400472 — A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (RECRUITING) PHASE1 NCT00002628 — Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer (UNKNOWN) PHASE1, PHASE2 NCT04681911 — Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT03134638 — A Study of SY-1365 in Adult Patients With Advanced Solid Tumors (TERMINATED) PHASE1 NCT01560663 — Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer (UNKNOWN) NCT05430347 — Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer (UNKNOWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 Published literature Cochrane review Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis (Expert review of anticancer therapy, 2026) Cochrane review Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis (Discover oncology, 2025) Cochrane review Efficacy and safety of neoadjuvant ICI combined with chemotherapy in breast cancer from the perspective of a privileged population: a systematic review and meta-analysis (International journal of surgery (London, England), 2025) Cochrane review Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis (Current problems in cancer, 2024) Cochrane review Platinum-based chemotherapy for early triple-negative breast cancer (The Cochrane database of systematic reviews, 2023) Meta-analysis Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: An updated systematic review and meta-analysis (Medicine, 2025) Meta-analysis Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis (Breast cancer research and treatment, 2025) Meta-analysis The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis (Scientific reports, 2025) Systematic review A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence (International journal of molecular sciences, 2026) Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer (ESMO open, 2026) Clinical trial publication Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study (Breast cancer research and treatment, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
CARFILZOMIB Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CEFONICID SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CEFPODOXIME PROXETIL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CERIVASTATIN SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CHENODEOXYCHOLIC ACID Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORDIAZEPOXIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORHEXIDINE GLUCONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORMADINONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CHLOROTRIANISENE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROXINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORPROMAZINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CHOLECALCIFEROL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CICLESONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 17 Cochrane 14 Meta-analysis 328 Trial pubs 95 RCT View evidence Registry trials NCT07372079 — Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy (NOT_YET_RECRUITING) PHASE2 NCT00191854 — Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line (COMPLETED) PHASE2 NCT02544243 — Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT06746870 — A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer (NOT_YET_RECRUITING) PHASE2 NCT00003269 — Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors (COMPLETED) PHASE2 NCT03387085 — QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (TERMINATED) PHASE1, PHASE2 NCT04159818 — Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (RECRUITING) PHASE2 NCT02879513 — Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy (UNKNOWN) PHASE3 Published literature Cochrane review Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis (Discover oncology, 2025) Cochrane review Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis (Current problems in cancer, 2024) Cochrane review Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis (Cancer pathogenesis and therapy, 2024) Cochrane review 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023) Cochrane review Platinum-based chemotherapy for early triple-negative breast cancer (The Cochrane database of systematic reviews, 2023) Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors (Cancer medicine, 2026) Meta-analysis Are hydrogels suitable for delivery of cisplatin to the microenvironment in breast cancer treatment: a meta-analysis (Therapeutic delivery, 2025) Meta-analysis Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis (European urology oncology, 2024) Meta-analysis The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis (Medicine, 2022) Systematic review Reawakening the master switches in triple-negative breast cancer: A strategic blueprint for confronting metastasis and chemoresistance via microRNA-200/205: A systematic review (Critical reviews in oncology/hematology, 2024) Clinical trial publication A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer (ESMO open, 2026) Clinical trial publication Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial (Scientific reports, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
CLASCOTERONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOBETASOL PROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOCORTOLONE PIVALATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CLOFARABINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CLOTRIMAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CODEINE ANHYDROUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
COLCHICINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CROMOLYN SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CYCLANDELATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
CYPROTERONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
DACTINOMYCIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DANAZOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DAROLUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DASATINIB ANHYDROUS Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DAUNORUBICIN HYDROCHLORIDE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT06190600 — Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy (ACTIVE_NOT_RECRUITING) NA NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT00944047 — Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression (COMPLETED) PHASE2 NCT01697293 — PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (TERMINATED) PHASE1, PHASE2 NCT00574236 — Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer (TERMINATED) PHASE2 NCT02115152 — Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer (UNKNOWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
DAUNORUBICIN LIPOSOMAL Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
DEFERASIROX Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DEFLAZACORT Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DESERPIDINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DESLANOSIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DESOGESTREL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DESONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DESOXIMETASONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DESOXYCORTICOSTERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DESOXYCORTICOSTERONE PIVALATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DEXAMETHASONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIDANOSINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLCARBAMAZINE CITRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLSTILBESTROL Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIFLORASONE DIACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DIFLUPREDNATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DIGITOXIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DIGOXIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DIPHENOXYLATE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DIPYRIDAMOLE Repurposing via BRCA1	Small molecule	Approved	Strong	95	3 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Myocardial perfusion imaging in breast cancer patients treated with or without post-mastectomy radiotherapy (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2000) Clinical trial publication Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer (Investigational new drugs, 1994) Clinical trial publication Phase I trial of dipyridamole with 5-fluorouracil and folinic acid (Cancer research, 1990) CT.gov search · Cochrane · PubMed	DGIdb	—
DISULFIRAM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DOFETILIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 1 Meta-analysis 6 Trial pubs 5 RCT View evidence Registry trials NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (RECRUITING) NA NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT02423356 — Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin (COMPLETED) NCT00584766 — Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer (COMPLETED) PHASE2 NCT06190600 — Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy (ACTIVE_NOT_RECRUITING) NA NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT00944047 — Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression (COMPLETED) PHASE2 NCT01697293 — PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (TERMINATED) PHASE1, PHASE2 Published literature Meta-analysis Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens (British journal of cancer, 1993) Clinical trial publication Bioequivalence of two doxorubicin liposome formulations (LY01612 and Caelyx) using free and encapsulated doxorubicin concentrations in Chinese patients with advanced breast cancer (International journal of clinical pharmacology and therapeutics, 2025) Clinical trial publication A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer (Journal of cancer research and clinical oncology, 2025) Clinical trial publication Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study (Breast cancer research and treatment, 2023) Clinical trial publication Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial (JAMA surgery, 2020) Clinical trial publication Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results (JAMA, 1995) CT.gov search · Cochrane · PubMed	DGIdb	—
DROMOSTANOLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DRONEDARONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DROSPIRENONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DULOXETINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DURVALUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
DUTASTERIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DYCLONINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DYDROGESTERONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ECONAZOLE NITRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EFAVIRENZ Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ENZALUTAMIDE Repurposing via BRCA2	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIGALLOCATECHIN GALLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing via AKT1	Small molecule	Approved	Strong	95	8 trials 11 Cochrane 21 Meta-analysis 975 Trial pubs 561 RCT View evidence Registry trials NCT00003577 — Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer (COMPLETED) PHASE3 NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 NCT02115152 — Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer (UNKNOWN) PHASE2 NCT01036087 — Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (COMPLETED) PHASE2 NCT05909332 — Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) (RECRUITING) PHASE3 NCT01996267 — Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (ACTIVE_NOT_RECRUITING) PHASE3 NCT00003012 — Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer (COMPLETED) PHASE3 NCT01159236 — Molecular Triaging of Newly Diagnosed Breast Cancer (WITHDRAWN) NA Published literature Cochrane review Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials (Cardio-oncology (London, England), 2025) Cochrane review Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis (BMC women's health, 2025) Cochrane review The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis (Current oncology (Toronto, Ont.), 2024) Cochrane review Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis (Cancer medicine, 2024) Cochrane review Effects of Integrated Chinese Traditional Medicine and Conventional Western Medicine on the Quality of Life of Breast Cancer Patients: A Systematic Review and Meta-Analysis (Evidence-based complementary and alternative medicine : eCAM, 2022) Meta-analysis Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer (World journal of surgical oncology, 2021) Meta-analysis Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021) Systematic review [Effect of taste perception on nutritional status in patients with breast cancer: a systematic review] (Nutricion hospitalaria, 2025) Clinical trial publication Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA) (JCO global oncology, 2026) Clinical trial publication Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) Clinical trial publication Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (Annals of surgical oncology, 2026) Clinical trial publication Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial (BMJ (Clinical research ed.), 2025) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ERGOCALCIFEROL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ERLOTINIB Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRADIOL 3-BENZOATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRADIOL CYPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRADIOL VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRAMUSTINE Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRAMUSTINE PHOSPHATE SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ESTRIOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ESTRONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHACRYNIC ACID Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHINYL ESTRADIOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHOXZOLAMIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHYLESTRENOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHYNODIOL DIACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ETONOGESTREL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ETOPOSIDE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
EVEROLIMUS Repurposing via AKT2	Small molecule	Approved	Strong	95	—	DGIdb	—
EXEMESTANE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
EXIFONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FEBUXOSTAT Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOFIBRATE MICRONIZED Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOLDOPAM MESYLATE Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FENRETINIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FENTANYL CITRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FEPRAZONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FINASTERIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUCYTOSINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUDARABINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUDROCORTISONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing via AKT1	Small molecule	Approved	Strong	95	1 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT05435911 — Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol (COMPLETED) NA Published literature Clinical trial publication Effects of remimazolam vs. an etomidate-propofol mixture on postoperative cognitive function in elderly female patients undergoing radical mastectomy for breast cancer: a randomized controlled trial (Frontiers in medicine, 2025) Clinical trial publication Comparison of recovery profiles between total intravenous anaesthesia with propofol or remimazolam reversed with flumazenil in patients undergoing breast surgery: A randomised controlled trial (European journal of anaesthesiology, 2024) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
FLUNISOLIDE ANHYDROUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOCINOLONE ACETONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOROMETHOLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOROURACIL Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUOXETINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FLUOXYMESTERONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUPREDNISOLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FLURANDRENOLIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUSPIRILENE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
FULVESTRANT Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
GEFITINIB Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
GEMCITABINE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 8 Cochrane 13 Meta-analysis 323 Trial pubs 103 RCT View evidence Registry trials NCT04681911 — Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT01133912 — Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) (COMPLETED) PHASE1 NCT00662129 — Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer (COMPLETED) PHASE2 NCT00191854 — Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line (COMPLETED) PHASE2 NCT02046421 — Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (COMPLETED) PHASE1 NCT02139358 — Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT02544243 — Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT06481553 — RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody (UNKNOWN) Published literature Cochrane review Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials (Medicina (Kaunas, Lithuania), 2024) Cochrane review Radiation recall dermatitis: A review of the literature (Seminars in oncology, 2022) Cochrane review Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer (BMC cancer, 2021) Cochrane review The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety (Oncology research and treatment, 2021) Cochrane review Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis (Pharmacotherapy, 2019) Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors (Cancer medicine, 2026) Systematic review Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review (The Lancet. Oncology, 2011) Systematic review The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review (European journal of cancer (Oxford, England : 1990), 2009) Systematic review Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer (Journal of the National Cancer Institute, 2008) Systematic review Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review (Health technology assessment (Winchester, England), 2008) Clinical trial publication A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer (ESMO open, 2026) Clinical trial publication Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study (Annals of oncology : official journal of the European Society for Medical Oncology, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
GEMCITABINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GENTIAN VIOLET CATION Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
GESTODENE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
GLUTATHIONE DISULFIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
GLYCYRRHIZIC ACID Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
GRISEOFULVIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
HALCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
HALOBETASOL PROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HALOPERIDOL DECANOATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
HALOPROGIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
HEXACHLOROPHENE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROCORTISONE BUTYRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE PROBUTATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE SODIUM PHOSPHATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE SODIUM SUCCINATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROCORTISONE VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
HYDROXYUREA Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
IBRUTINIB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
IDARUBICIN Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
IDARUBICIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
IDEBENONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDINAVIR SULFATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
INDOMETHACIN Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IOPAMIDOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
IPILIMUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
IRINOTECAN HYDROCHLORIDE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOPROPYL UNOPROSTONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOTRETINOIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
LACTATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
LEUCOVORIN CALCIUM Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
LEUPROLIDE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVODOPA Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
LIOTHYRONINE SODIUM Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
LOPERAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
LORACARBEF Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LORATADINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
LOTEPREDNOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
LOVASTATIN Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
LULICONAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAPROTILINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MASOPROCOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MECAMYLAMINE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECHLORETHAMINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MEDROXYPROGESTERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MEDRYSONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MEGESTROL ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MELOXICAM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MELPHALAN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHOBARBITAL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPREDNISONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MESTRANOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
METFORMIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHANDROSTENOLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via AKT1	Small molecule	Approved	Strong	95	2 trials View evidence Registry trials NCT04389281 — X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (RECRUITING) PHASE1 NCT04720664 — Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
METHYLDOPA ANHYDROUS Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLENE BLUE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHYLENE BLUE ANHYDROUS Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHYLPREDNISOLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLPREDNISOLONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHYLTESTOSTERONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
METIPRANOLOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
METOPROLOL Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIBEFRADIL DIHYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MIDAZOLAM HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MIFEPRISTONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MILTEFOSINE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
MINOCYCLINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MITOMYCIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	4 trials 119 Trial pubs 60 RCT View evidence Registry trials NCT01196455 — Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT02299999 — SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT01091168 — Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer (COMPLETED) PHASE3 NCT00003893 — Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer (COMPLETED) PHASE3 Published literature Systematic review A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer (Health technology assessment (Winchester, England), 2000) Clinical trial publication Role of Mitomycin C in Preventing Capsular Contracture in Implant-Based Reconstructive Breast Surgery: A Randomized Controlled Trial (Plastic and reconstructive surgery, 2017) Clinical trial publication Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer (Onkologie, 2012) Clinical trial publication Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer (Breast cancer research : BCR, 2012) Clinical trial publication Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer (Neoplasma, 2011) Clinical trial publication Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer (European radiology, 2010) Randomized controlled trial Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer (The American journal of Chinese medicine, 2008) Randomized controlled trial Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival (Annals of oncology : official journal of the European Society for Medical Oncology, 2005) CT.gov search · Cochrane · PubMed	DGIdb	—
MITOTANE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
MITOXANTRONE Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
MITOXANTRONE HYDROCHLORIDE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 5 Trial pubs 2 RCT View evidence Registry trials NCT06156761 — Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer (UNKNOWN) NA NCT02596373 — A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT00002498 — Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer (UNKNOWN) PHASE2 NCT00002544 — Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer (COMPLETED) PHASE3 NCT00010075 — Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT04927481 — A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer (TERMINATED) PHASE2 NCT00003068 — High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer (COMPLETED) PHASE2 NCT05582499 — Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (RECRUITING) PHASE2 Published literature Clinical trial publication Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study (BMC medicine, 2026) Clinical trial publication Discovery of fluorescent properties in mitoxantrone hydrochloride injection for tracing: application for sentinel lymph node biopsy in breast cancer (World journal of surgical oncology, 2026) Clinical trial publication A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer (BMC cancer, 2025) Clinical trial publication Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial (Investigational new drugs, 2022) Clinical trial publication 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer (Breast cancer (Tokyo, Japan), 2001) CT.gov search · Cochrane · PubMed	DGIdb	—
MITOXANTRONE HYDROCHLORIDE Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MOCLOBEMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MOMETASONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MORICIZINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MYCOPHENOLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
MYCOPHENOLATE MOFETIL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NAFTIFINE HYDROCHLORIDE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NANDROLONE DECANOATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NANDROLONE PHENPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEFAZODONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NELFINAVIR Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NICARDIPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NICARDIPINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NICOTINE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NIFEDIPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NILUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NINTEDANIB ESYLATE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
NIRAPARIB Repurposing via BRCA1	Small molecule	Approved	Strong	95	—	DGIdb	—
NISOLDIPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NITAZOXANIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NITROFURAZONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NIVOLUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
NORELGESTROMIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
NORETHINDRONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NORETHINDRONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORETHYNODREL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORGESTIMATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NORGESTREL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
NORTRIPTYLINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
O-PHENANTHROLINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
OCTOCRYLENE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
OFLOXACIN Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLAPARIB Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 8 Cochrane 12 Meta-analysis 64 Trial pubs 26 RCT View evidence Registry trials NCT06197581 — Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RECRUITING) NA NCT06797635 — Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (RECRUITING) PHASE2 NCT01445418 — AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer (COMPLETED) PHASE1 NCT06175390 — Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT00516724 — Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel (COMPLETED) PHASE1 NCT05174832 — Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients (UNKNOWN) PHASE2 NCT02898207 — Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (COMPLETED) PHASE1 NCT02561832 — A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer (TERMINATED) PHASE1 Published literature Cochrane review Dose reduction of olaparib in older patients: Insights from an analysis of a National Database in Japan (The journal of obstetrics and gynaecology research, 2023) Cochrane review PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis (Hematology/oncology and stem cell therapy, 2023) Cochrane review Cost-effectiveness of PARP inhibitors in malignancies: A systematic review (PloS one, 2022) Cochrane review Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis (Expert opinion on drug safety, 2023) Cochrane review Comparison of Adverse Reactions Caused by Olaparib for Different Indications (Frontiers in pharmacology, 2022) Meta-analysis Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis (European journal of clinical pharmacology, 2025) Meta-analysis Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis (Frontiers in immunology, 2024) Meta-analysis Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis (European urology oncology, 2024) Meta-analysis PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology (Breast (Edinburgh, Scotland), 2022) Systematic review Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review (The breast journal, 2024) Clinical trial publication Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) Clinical trial publication TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
OXALIPLATIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 3 Meta-analysis 34 Trial pubs 11 RCT View evidence Registry trials NCT05576077 — A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (TERMINATED) PHASE1 NCT00674206 — A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer (TERMINATED) PHASE2 NCT02077998 — Oxaliplatin in Treating Patients With Metastatic Breast Cancer (COMPLETED) EARLY_PHASE1 NCT07464769 — Compression Therapy of Hands and Feet for the Prevention of Taxane- or Oxaliplatin-induced Peripheral Neuropathy (NOT_YET_RECRUITING) NA NCT03009058 — Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (TERMINATED) PHASE1, PHASE2 NCT03838406 — BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer (COMPLETED) NA NCT01937507 — Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer (TERMINATED) PHASE2 NCT01233505 — Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (TERMINATED) PHASE1 Published literature Cochrane review Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials (British journal of clinical pharmacology, 2014) Cochrane review KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis (Ontario health technology assessment series, 2010) Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors (Cancer medicine, 2026) Meta-analysis Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers (Cancer, 2006) Systematic review Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy (Journal of vascular and interventional radiology : JVIR, 2024) Systematic review Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies-An Update Overview (Molecules (Basel, Switzerland), 2023) Clinical trial publication Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study (Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026) Clinical trial publication Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025) Clinical trial publication Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study) (BMC cancer, 2023) Clinical trial publication An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer (Clinical cancer research : an official journal of the American Association for Cancer Research, 2023) Clinical trial publication A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) (Cancer research and treatment, 2023) Randomized controlled trial A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy (Scientific reports, 2022) CT.gov search · Cochrane · PubMed	DGIdb	—
OXANDROLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
OXAZEPAM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETHOLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYPHENISATIN ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PACLITAXEL PROTEIN-BOUND Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT00019812 — Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 (COMPLETED) PHASE2 NCT00724386 — Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer (COMPLETED) PHASE1 NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (RECRUITING) NA NCT02824575 — Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (TERMINATED) PHASE1 NCT00251472 — A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer (COMPLETED) PHASE2 NCT03873272 — The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL (COMPLETED) NA NCT06190600 — Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy (ACTIVE_NOT_RECRUITING) NA NCT02067416 — PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (WITHDRAWN) PHASE2 Published literature Systematic review The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review (European journal of cancer (Oxford, England : 1990), 2009) Clinical trial publication FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1 (Clinical cancer research : an official journal of the American Association for Cancer Research, 2020) Clinical trial publication Bioequivalence of paclitaxel protein-bound particles in patients with breast cancer: determining total and unbound paclitaxel in plasma by rapid equilibrium dialysis and liquid chromatography-tandem mass spectrometry (Drug design, development and therapy, 2019) CT.gov search · Cochrane · PubMed	DGIdb	—
PARAMETHASONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PAROXETINE HYDROCHLORIDE, HEMIHYDRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PAZOPANIB Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PEMBROLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
PENTAMIDINE ISETHIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERHEXILINE MALEATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERMETHRIN Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENELZINE SULFATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENFORMIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PIMOZIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PIPERINE Repurposing via BRCA1	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study (Phytotherapy research : PTR, 2025) CT.gov search · Cochrane · PubMed	DGIdb	—
PITAVASTATIN CALCIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PODOFILOX Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PRASTERONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZEPAM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PREDNICARBATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PREDNISOLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PREDNISOLONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PREDNISONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PRIMIDONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PROBENECID Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PROGESTERONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PROMAZINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROMETHAZINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PYRIDOSTIGMINE BROMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PYRIMETHAMINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PYRITHIONE ZINC Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
PYRVINIUM PAMOATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
QUERCETIN Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
QUININE SULFATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RABEPRAZOLE SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RALOXIFENE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
REPAGLINIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
RESERPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
RESVERATROL Repurposing via BRCA1	Small molecule	Approved	Strong	95	3 trials 1 Meta-analysis 4 Trial pubs 3 RCT View evidence Registry trials NCT04266353 — Effect of Resveratrol on Serum IGF2 Among African American Women (WITHDRAWN) NA NCT05306002 — Nutritional Intervention and DNA Damage of Patients With HBOC (COMPLETED) NA NCT03482401 — Disposition of Dietary Polyphenols and Methylxanthines in Mammary Tissues From Breast Cancer Patients (COMPLETED) NA Published literature Meta-analysis Sulforaphane and Epigallocatechin Gallate Restore Estrogen Receptor Expression by Modulating Epigenetic Events in the Breast Cancer Cell Line MDA-MB-231: A Systematic Review and Meta-Analysis (Journal of nutrigenetics and nutrigenomics, 2017) Systematic review The Relationship Between Climate Change and Breast Cancer and Its Management and Preventative Implications in South Africa (International journal of environmental research and public health, 2025) Systematic review Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies-An Update Overview (Molecules (Basel, Switzerland), 2023) Systematic review Endocrine disrupting chemicals and breast cancer: a systematic review of epidemiological studies (Critical reviews in food science and nutrition, 2022) Clinical trial publication Disposition of Dietary Polyphenols in Breast Cancer Patients' Tumors, and Their Associated Anticancer Activity: The Particular Case of Curcumin (Molecular nutrition & food research, 2021) Clinical trial publication Metabolic Profiling of Dietary Polyphenols and Methylxanthines in Normal and Malignant Mammary Tissues from Breast Cancer Patients (Molecular nutrition & food research, 2019) Clinical trial publication A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones (Journal of translational medicine, 2014) Clinical trial publication Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer (Nutrition and cancer, 2012) CT.gov search · Cochrane · PubMed	DGIdb	—
RIBOFLAVIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	2 trials 1 Meta-analysis 9 Trial pubs 7 RCT View evidence Registry trials NCT04669119 — Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy. (UNKNOWN) PHASE4 NCT00204490 — Soy Isoflavones and Breast Cancer Risk Reduction (COMPLETED) PHASE2 Published literature Meta-analysis Association Between One-carbon Metabolism-related Vitamins and Risk of Breast Cancer: A Systematic Review and Meta-analysis of Prospective Studies (Clinical breast cancer, 2020) Clinical trial publication Ticagrelor modestly raises plasma riboflavin concentration in humans and inhibits riboflavin transport by BCRP and MRP4 (Clinical pharmacology and therapeutics, 2024) Clinical trial publication A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants (The Journal of pharmacology and experimental therapeutics, 2024) Clinical trial publication Dietary intake of selected B vitamins in relation to risk of major cancers in women (British journal of cancer, 2008) Clinical trial publication Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy (Vascular pharmacology, 2008) Clinical trial publication Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy (The British journal of nutrition, 2008) CT.gov search · Cochrane · PubMed	DGIdb	—
RIFAMPIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
RIFAMYCIN SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RIFAPENTINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
RIMONABANT Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ROCURONIUM BROMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RUCAPARIB Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 1 Cochrane 3 Meta-analysis 5 Trial pubs View evidence Registry trials NCT03911453 — Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors (COMPLETED) EARLY_PHASE1 NCT03542175 — A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy (COMPLETED) PHASE1 NCT00664781 — Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer (COMPLETED) PHASE2 NCT02505048 — A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature (COMPLETED) PHASE2 NCT04171700 — A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes (TERMINATED) PHASE2 NCT03101280 — A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer (COMPLETED) PHASE1 NCT02711137 — Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies (TERMINATED) PHASE1, PHASE2 NCT03992131 — A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (TERMINATED) PHASE1, PHASE2 Published literature Cochrane review Cost-effectiveness of PARP inhibitors in malignancies: A systematic review (PloS one, 2022) Meta-analysis Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis (Journal of chemotherapy (Florence, Italy), 2025) Meta-analysis Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis (European urology oncology, 2024) Meta-analysis Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis (European journal of cancer (Oxford, England : 1990), 2021) Systematic review The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review (International journal of molecular sciences, 2022) Clinical trial publication PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers (British journal of cancer, 2024) Clinical trial publication A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR) (The oncologist, 2024) Clinical trial publication Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation (European journal of cancer (Oxford, England : 1990), 2021) Clinical trial publication Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer (Nature communications, 2020) Clinical trial publication Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer (British journal of cancer, 2016) CT.gov search · Cochrane · PubMed	DGIdb	—
SACITUZUMAB GOVITECAN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 16 Cochrane 19 Meta-analysis 31 Trial pubs 18 RCT View evidence Registry trials NCT04320693 — Expanded Access for IMMU-132 (APPROVED_FOR_MARKETING) NCT06612203 — Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT07046455 — Trop-2 Targeted PET Probes in Advanced TNBC (RECRUITING) NA NCT05774886 — Implantable Microdevice for TNBC - Pilot Study (WITHDRAWN) PHASE1 NCT06102824 — Organoid-based Functional Precision Therapy for Advanced Breast Cancer (RECRUITING) PHASE2 NCT07582887 — Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response (RECRUITING) NCT05840211 — Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ACTIVE_NOT_RECRUITING) PHASE3 NCT06462092 — Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency: a Bayesian network meta-analysis (BMC cancer, 2026) Cochrane review Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review (BMC cancer, 2026) Cochrane review Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis (Frontiers in pharmacology, 2025) Cochrane review The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data (Frontiers in immunology, 2025) Cochrane review Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis (Frontiers in oncology, 2025) Meta-analysis Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis (European journal of clinical pharmacology, 2026) Meta-analysis Pre-Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta-Analysis and Recommendation (Clinical and translational science, 2026) Systematic review Comparing the Efficacy of Various Treatment Strategies for Patients With Advanced Triple-Negative Breast Cancer: An Umbrella Review (Clinical pharmacology and therapeutics, 2026) Systematic review Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials (Frontiers in immunology, 2025) Clinical trial publication Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer (The New England journal of medicine, 2026) Clinical trial publication Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study (Annals of oncology : official journal of the European Society for Medical Oncology, 2026) Clinical trial publication Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer (The New England journal of medicine, 2025) CT.gov search · Cochrane · PubMed	DGIdb	—
SALMETEROL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
SAQUINAVIR MESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SELUMETINIB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
SERTINDOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
SERTRALINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SIMVASTATIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing via AKT1	Small molecule	Approved	Strong	95	8 trials 2 Trial pubs View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT03805399 — FUSCC Refractory TNBC Umbrella (FUTURE) (UNKNOWN) PHASE1, PHASE2 NCT02520063 — Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT01088893 — Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy (UNKNOWN) PHASE2 NCT03659136 — The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread (COMPLETED) PHASE2 NCT05983107 — Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (RECRUITING) PHASE2 NCT01111825 — Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT02809404 — Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) (COMPLETED) Published literature Systematic review mTOR inhibitors in breast cancer: a systematic review (Gynecologic oncology, 2012) Clinical trial publication Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy (Breast cancer research and treatment, 2015) Clinical trial publication Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer (Investigational new drugs, 2010) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SORAFENIB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
SORAFENIB TOSYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SOTALOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
SPARFLOXACIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
SPIRONOLACTONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
STANOZOLOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
SULBACTAM Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SULFACARBAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SULFISOXAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TACROLIMUS ANHYDROUS Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TALAZOPARIB Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 6 Cochrane 8 Meta-analysis 23 Trial pubs 8 RCT View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT04987931 — Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer (COMPLETED) NCT05141708 — Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m (COMPLETED) NCT03964532 — TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT04703920 — Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer (COMPLETED) PHASE1 NCT05035745 — Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) (RECRUITING) PHASE1, PHASE2 NCT02358200 — Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer (TERMINATED) PHASE1 NCT06735742 — A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer (ACTIVE_NOT_RECRUITING) Published literature Cochrane review Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis (Cancer pathogenesis and therapy, 2024) Cochrane review PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis (Hematology/oncology and stem cell therapy, 2023) Cochrane review Cost-effectiveness of PARP inhibitors in malignancies: A systematic review (PloS one, 2022) Cochrane review Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis (Expert opinion on drug safety, 2023) Cochrane review Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review (PharmacoEconomics, 2022) Meta-analysis Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis (Journal of chemotherapy (Florence, Italy), 2025) Meta-analysis Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis (European urology oncology, 2024) Meta-analysis PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology (Breast (Edinburgh, Scotland), 2022) Meta-analysis Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer (Cancer treatment reviews, 2022) Systematic review Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review (The breast journal, 2024) Clinical trial publication A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer (Cancer, 2026) Clinical trial publication Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion (Proceedings of the National Academy of Sciences of the United States of America, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
TAMOXIFEN CITRATE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 11 Trial pubs 9 RCT View evidence Registry trials NCT02188745 — ER Reactivation Therapy for Breast Cancer (COMPLETED) PHASE2 NCT00032136 — Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer (COMPLETED) PHASE3 NCT01712893 — Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer (COMPLETED) PHASE3 NCT00107263 — Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer (COMPLETED) PHASE3 NCT02517593 — Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake (COMPLETED) PHASE1, PHASE2 NCT02747004 — A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT02936206 — Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. (TERMINATED) PHASE1 NCT00793377 — Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer (COMPLETED) PHASE3 Published literature Cochrane review Drug use evaluation of tamoxifen focusing on off-label use in a managed care population in Israel (Journal of managed care pharmacy : JMCP, 2010) Cochrane review Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer (Annals of internal medicine, 2009) Clinical trial publication [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)] (Gan to kagaku ryoho. Cancer & chemotherapy, 1998) Clinical trial publication Long-term tamoxifen citrate use and potential ocular toxicity (American journal of ophthalmology, 1998) Clinical trial publication Effect of tamoxifen on measurements of hemostasis in healthy women (Archives of internal medicine, 1996) Clinical trial publication Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years (Archives of internal medicine, 1994) Clinical trial publication Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994) Randomized controlled trial Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women (Breast cancer research and treatment, 1994) CT.gov search · Cochrane · PubMed	DGIdb	—
TAMOXIFEN CITRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TAMSULOSIN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TANNIC ACID Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TAZOBACTAM Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TELITHROMYCIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TEMOZOLOMIDE Repurposing via BRCA2	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOLACTONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOSTERONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOSTERONE CYPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOSTERONE ENANTHATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TESTOSTERONE PROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
THIABENDAZOLE Repurposing via BRCA1	Small molecule	Approved	Strong	95	4 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
THIOCTIC ACID Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
THIOGUANINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
THIOTEPA Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TIOCONAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLVAPTAN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TOPOTECAN HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TOPOTECAN HYDROCHLORIDE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
TOREMIFENE CITRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRAMETINIB DIMETHYL SULFOXIDE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
TRASTUZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIAMCINOLONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIAMCINOLONE DIACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRIAMTERENE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIBROMSALAN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRICLOSAN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIFLUOPERAZINE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
TRILOSTANE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIMETREXATE Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIPARANOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing via AKT1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALPROIC ACID Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
VALRUBICIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VANDETANIB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
VEMURAFENIB Repurposing via AKT3	Small molecule	Approved	Strong	95	—	DGIdb	—
VENETOCLAX Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
VINBLASTINE SULFATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VINCRISTINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
VINORELBINE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 8 Cochrane 10 Meta-analysis 430 Trial pubs 105 RCT View evidence Registry trials NCT03321981 — MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (COMPLETED) PHASE2 NCT00724386 — Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer (COMPLETED) PHASE1 NCT04681911 — Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT00001944 — Vinorelbine and XR9576 to Treat Cancer (COMPLETED) PHASE1 NCT00912275 — Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer (COMPLETED) PHASE1, PHASE2 NCT02544243 — Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer (UNKNOWN) PHASE2 NCT05856383 — Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (RECRUITING) NCT07556848 — A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer (NOT_YET_RECRUITING) PHASE3 Published literature Cochrane review Metronomic chemotherapy combined with immunotherapy in solid tumor: a systematic review (Translational cancer research, 2026) Cochrane review Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss (Cancers, 2026) Cochrane review Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer (BMC cancer, 2021) Cochrane review Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis (BMC cancer, 2020) Cochrane review Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review  (International journal of clinical pharmacology and therapeutics, 2018) Meta-analysis A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer (Anticancer research, 2019) Meta-analysis Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies (Clinical breast cancer, 2016) Meta-analysis A systematic review of vinorelbine for the treatment of breast cancer (The breast journal, 2013) Systematic review Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review (The Lancet. Oncology, 2011) Clinical trial publication Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study (Annals of oncology : official journal of the European Society for Medical Oncology, 2026) Clinical trial publication Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial (The Lancet. Oncology, 2025) Clinical trial publication Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study (Breast (Edinburgh, Scotland), 2025) CT.gov search · Cochrane · PubMed	DGIdb	—
VINORELBINE TARTRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
VITAMIN A Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
VITAMIN K3 Repurposing via BLM	Small molecule	Approved	Strong	95	—	DGIdb	—
WARFARIN POTASSIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ZAFIRLUKAST Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ZIPRASIDONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ZOLPIDEM TARTRATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
DARAPLADIB Repurposing via AKT1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via AKT1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
GSK126 Repurposing via ARID1A	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via AKT1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

107 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Reishi Natural product Human Study A phase I/II trial of a polysaccharide extract from Maitake mushroom in…	Mushroom	Phase II	Moderate	23	2 trials View evidence Registry trials NCT02486796 — Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer (TERMINATED) PHASE1, PHASE2 NCT06028022 — Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors (RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
Vitamin D3 Natural product Meta-analysis Lower vitamin D levels and VDR variants are risk factors for breast can… Meta Analysis Review: there is a consistently strong inverse correlations with solar… Meta Analysis There is a highly significant linear dose-response relationship between…	Nutraceutical	Phase III	Moderate	20	8 trials 1 Meta-analysis 14 Trial pubs 11 RCT View evidence Registry trials NCT04091178 — Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer (COMPLETED) PHASE2 NCT01419730 — Vitamin D and Physical Activity on Bone Health (ACTIVE_NOT_RECRUITING) PHASE2 NCT00172068 — Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (TERMINATED) PHASE2 NCT05523609 — Vitamin D and Calcium Supplementation in Breast Cancer (UNKNOWN) PHASE2, PHASE3 NCT00263185 — High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status (COMPLETED) EARLY_PHASE1 NCT03629717 — RANKL Inhibition and Breast Tissue Biomarkers (COMPLETED) EARLY_PHASE1 NCT04147767 — Plant Sterol INtervention for Cancer Prevention (PINC) (UNKNOWN) NA NCT07334626 — Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy (RECRUITING) NA Published literature Meta-analysis Lower vitamin D levels and VDR variants are risk factors for breast cancer: an updated meta-analysis (Nucleosides, nucleotides & nucleic acids, 2023) CT.gov search · Cochrane · PubMed	Examine.com, GreenMedInfo	PubChem GreenMedInfo Examine.com
Vitamin D3 Natural product Meta-analysis Lower vitamin D levels and VDR variants are risk factors for breast can… Meta Analysis Vitamin supplement use during breast cancer treatment and survival redu…	Nutraceutical	Phase III	Emerging	19	8 trials 1 Meta-analysis 14 Trial pubs 11 RCT View evidence Registry trials NCT04091178 — Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer (COMPLETED) PHASE2 NCT01419730 — Vitamin D and Physical Activity on Bone Health (ACTIVE_NOT_RECRUITING) PHASE2 NCT00172068 — Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (TERMINATED) PHASE2 NCT05523609 — Vitamin D and Calcium Supplementation in Breast Cancer (UNKNOWN) PHASE2, PHASE3 NCT00263185 — High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status (COMPLETED) EARLY_PHASE1 NCT03629717 — RANKL Inhibition and Breast Tissue Biomarkers (COMPLETED) EARLY_PHASE1 NCT04147767 — Plant Sterol INtervention for Cancer Prevention (PINC) (UNKNOWN) NA NCT07334626 — Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy (RECRUITING) NA Published literature Meta-analysis Lower vitamin D levels and VDR variants are risk factors for breast cancer: an updated meta-analysis (Nucleosides, nucleotides & nucleic acids, 2023) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, Examine.com	PubChem Examine.com
Omega-3 Fatty Acids Natural product Cochrane review The effectiveness of omega-3 fatty acids on health outcomes in women wi… Cochrane review Systemic therapies for preventing or treating aromatase inhibitor-induc… Cochrane review Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Re…	Nutraceutical	Phase III	Emerging	19	8 trials 6 Cochrane 24 Trial pubs 21 RCT View evidence Registry trials NCT02352779 — Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors (COMPLETED) NA NCT01849250 — Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors (COMPLETED) PHASE2 NCT00723398 — Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention (COMPLETED) NA NCT02278965 — Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer (COMPLETED) PHASE1 NCT03764943 — Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction (COMPLETED) PHASE3 NCT02996240 — Breast, Omega 3 Free Fatty Acid, Ph 0 (COMPLETED) NA NCT02517502 — Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy (COMPLETED) EARLY_PHASE1 NCT02150525 — Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors (COMPLETED) PHASE2 Published literature Cochrane review The effectiveness of omega-3 fatty acids on health outcomes in women with breast cancer: A systematic review (Food science & nutrition, 2023) Cochrane review Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer (The Cochrane database of systematic reviews, 2022) Cochrane review Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies (Advances in nutrition (Bethesda, Md.), 2020) Cochrane review Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis (Maturitas, 2018) Cochrane review Dietary supplements and fatigue in patients with breast cancer: a systematic review (Breast cancer research and treatment, 2018) Clinical trial publication The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial (The Journal of nutritional biochemistry, 2025) Clinical trial publication The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial (Nutrients, 2024) Clinical trial publication The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial (Clinical nutrition ESPEN, 2025) Clinical trial publication A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2 (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023) Clinical trial publication Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo (Cancer prevention research (Philadelphia, Pa.), 2021) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Calcium Natural product Meta-analysis Association Between Dietary/Supplementary Calcium Intake and Risk of Br… Meta-analysis Clinical and prognostic significance of parathyroid hormone-related pro… Meta-analysis Effectiveness and safety of bone protective interventions to mitigate b…	Nutraceutical	Phase III	Emerging	19	8 trials 25 Meta-analysis 113 Trial pubs 75 RCT View evidence Registry trials NCT04091178 — Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer (COMPLETED) PHASE2 NCT00637481 — A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer (COMPLETED) PHASE1 NCT01419730 — Vitamin D and Physical Activity on Bone Health (ACTIVE_NOT_RECRUITING) PHASE2 NCT03554109 — QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (WITHDRAWN) PHASE2 NCT02834403 — L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (COMPLETED) PHASE1, PHASE2 NCT00172068 — Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (TERMINATED) PHASE2 NCT05523609 — Vitamin D and Calcium Supplementation in Breast Cancer (UNKNOWN) PHASE2, PHASE3 NCT03249389 — Assessing the Changes in Markers of Calcium Vitamin Metabolism of for Breast Cancer Adjuvant (CALCIOBS) (COMPLETED) NA Published literature Meta-analysis Association Between Dietary/Supplementary Calcium Intake and Risk of Breast Cancer: A Systematic Review and Meta-Analysis of Cohort Studies (Nutrition and cancer, 2026) Meta-analysis Clinical and prognostic significance of parathyroid hormone-related protein in breast cancer: a systematic review and meta-analyses of observational studies in women (Endocrine-related cancer, 2026) Meta-analysis Effectiveness and safety of bone protective interventions to mitigate bone loss and skeletal fractures experienced by patients with non-metastatic breast cancer: a systematic review and meta-analysis (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026) Meta-analysis Dietary intake and cancer incidence in Korean adults: a systematic review and meta-analysis of observational studies (Epidemiology and health, 2023) Meta-analysis Association between calcium intake and risk of breast cancer: An updated systematic review and dose-response meta-analysis of cohort studies (Clinical nutrition ESPEN, 2023) Systematic review Stachydrine: A Systematic Review of Its Multi-Targeted Therapeutic Potential in Cardiovascular, Oncology, Renal, Gynecological, and Inflammatory Disorders (Drug design, development and therapy, 2026) Systematic review Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis (Frontiers in oncology, 2025) Clinical trial publication Differential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients (Pakistan journal of pharmaceutical sciences, 2026) Clinical trial publication In Vitro and Clinical Evaluations of UGT1A1-, P-gp-, OATP1B1-, and BCRP-Mediated Drug-Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor (Journal of clinical pharmacology, 2025) Clinical trial publication Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients (The Journal of clinical endocrinology and metabolism, 2025) Clinical trial publication Oxidized Regenerated Cellulose Versus Calcium Alginate in Controlling Bleeding From Malignant Wounds: A Randomized Controlled Trial (Cancer nursing, 2024) Clinical trial publication Soy isoflavones decrease fibroglandular breast tissue measured by magnetic resonance imaging in premenopausal women: A 2-year randomized double-blind placebo controlled clinical trial (Clinical nutrition ESPEN, 2022) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin B12 Natural product Systematic review From Micro to Macro: Understanding the Far-Reaching Consequences of B12… Systematic review Elevated Vitamin B12, Risk of Cancer, and Mortality: A Systematic Review Systematic review Safety and efficacy of vitamin B in cancer treatments: A systematic rev…	Nutraceutical	Approved	Emerging	19	8 trials 10 Trial pubs 6 RCT View evidence Registry trials NCT07344974 — Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity (NOT_YET_RECRUITING) PHASE4 NCT06517420 — Effect of Kefir on Symptom Management and Quality of Life in Oncology (COMPLETED) NA NCT02795572 — Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy (TERMINATED) PHASE2 NCT04150042 — SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (RECRUITING) PHASE1 NCT03069313 — Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms (COMPLETED) NA NCT02824575 — Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (TERMINATED) PHASE1 NCT06883201 — Application of Patient Blood Management in the Oncology Patient Affected by Breast Cancer (RECRUITING) NCT01118624 — Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer (COMPLETED) PHASE2 Published literature Systematic review From Micro to Macro: Understanding the Far-Reaching Consequences of B12 Deficiency on Women's Health (Public health nursing (Boston, Mass.), 2025) Systematic review Elevated Vitamin B12, Risk of Cancer, and Mortality: A Systematic Review (Cancer investigation, 2024) Systematic review Safety and efficacy of vitamin B in cancer treatments: A systematic review (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2024) Clinical trial publication Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial (Clinical breast cancer, 2022) Clinical trial publication Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221) (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020) Clinical trial publication Monitoring Vitamin B(12) in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases (Nutrients, 2019) Clinical trial publication Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer (The breast journal, 2018) Clinical trial publication Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32 (Breast cancer research and treatment, 2017) Randomized controlled trial Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial (JAMA, 2008) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Melatonin Natural product Meta-analysis Light at night exposure and risk of breast cancer: a meta-analysis of o… Meta-analysis Prevention of depression in adults with long-term physical conditions Meta-analysis Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case-Contro…	Nutraceutical	Phase III	Moderate	17	8 trials 11 Meta-analysis 31 Trial pubs 21 RCT View evidence Registry trials NCT02486796 — Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer (TERMINATED) PHASE1, PHASE2 NCT04364347 — Chemotherapy-induced Circadian Rhythm Disruption (UNKNOWN) NCT00506064 — Melatonin Postoperative Sleep Study in Breast Cancer Patients (TERMINATED) PHASE1 NCT06696378 — Melatonin Supplementation and Exercise Program in Breast Cancer Women (RECRUITING) NA NCT01355523 — The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients (TERMINATED) PHASE2, PHASE3 NCT03716583 — Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer (COMPLETED) PHASE2 NCT02883790 — Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients (TERMINATED) NA NCT02332928 — Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy (TERMINATED) PHASE3 Published literature Meta-analysis Light at night exposure and risk of breast cancer: a meta-analysis of observational studies (Frontiers in public health, 2023) Meta-analysis Prevention of depression in adults with long-term physical conditions (The Cochrane database of systematic reviews, 2021) Meta-analysis Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case-Control Analysis in the DOM Study and Meta-analysis of Prospective Studies (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021) Meta-analysis Exposure to light at night (LAN) and risk of breast cancer: A systematic review and meta-analysis (The Science of the total environment, 2021) Meta-analysis A meta-analysis of microRNA networks regulated by melatonin in cancer: Portrait of potential candidates for breast cancer treatment (Journal of pineal research, 2020) Systematic review Impact of Nutritional Supplements and Antioxidants in the Treatment of Breast Cancer: A Systematic Review (Nutrients, 2026) Systematic review Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review (Nutrients, 2025) Systematic review Antitumor effect of melatonin on breast cancer in experimental models: A systematic review (Biochimica et biophysica acta. Reviews on cancer, 2023) Systematic review Relationship between Night Shifts and Risk of Breast Cancer among Nurses: A Systematic Review (Medicina (Kaunas, Lithuania), 2020) Clinical trial publication Efficacy of Melatonin in Alleviating Radiotherapy-Induced Fatigue, Anxiety, and Depression in Breast Cancer Patients: A Randomized, Triple-Blind, Placebo-Controlled Trial (Integrative cancer therapies, 2025) Clinical trial publication Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial (The oncologist, 2024) Clinical trial publication Identification of prognostic melatonin-related lncRNA signature in tumor immune microenvironment and drug resistance for breast cancer (Asian journal of surgery, 2023) CT.gov search · Cochrane · PubMed	Examine.com, GreenMedInfo	PubChem GreenMedInfo Examine.com
Ashwagandha Natural product Clinical trial publication Effect of Withania somnifera (Ashwagandha) on the development of chemot…	Ayurvedic	Preclinical	Moderate	17	1 Trial pubs View evidence Published literature Clinical trial publication Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients (Integrative cancer therapies, 2013) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Melatonin Natural product Meta-analysis Light at night exposure and risk of breast cancer: a meta-analysis of o… Meta-analysis Prevention of depression in adults with long-term physical conditions Meta-analysis Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case-Contro…	Nutraceutical	Phase III	Emerging	16	8 trials 11 Meta-analysis 31 Trial pubs 21 RCT View evidence Registry trials NCT02486796 — Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer (TERMINATED) PHASE1, PHASE2 NCT04364347 — Chemotherapy-induced Circadian Rhythm Disruption (UNKNOWN) NCT00506064 — Melatonin Postoperative Sleep Study in Breast Cancer Patients (TERMINATED) PHASE1 NCT06696378 — Melatonin Supplementation and Exercise Program in Breast Cancer Women (RECRUITING) NA NCT01355523 — The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients (TERMINATED) PHASE2, PHASE3 NCT03716583 — Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer (COMPLETED) PHASE2 NCT02883790 — Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients (TERMINATED) NA NCT02332928 — Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy (TERMINATED) PHASE3 Published literature Meta-analysis Light at night exposure and risk of breast cancer: a meta-analysis of observational studies (Frontiers in public health, 2023) Meta-analysis Prevention of depression in adults with long-term physical conditions (The Cochrane database of systematic reviews, 2021) Meta-analysis Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case-Control Analysis in the DOM Study and Meta-analysis of Prospective Studies (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021) Meta-analysis Exposure to light at night (LAN) and risk of breast cancer: A systematic review and meta-analysis (The Science of the total environment, 2021) Meta-analysis A meta-analysis of microRNA networks regulated by melatonin in cancer: Portrait of potential candidates for breast cancer treatment (Journal of pineal research, 2020) Systematic review Impact of Nutritional Supplements and Antioxidants in the Treatment of Breast Cancer: A Systematic Review (Nutrients, 2026) Systematic review Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review (Nutrients, 2025) Systematic review Antitumor effect of melatonin on breast cancer in experimental models: A systematic review (Biochimica et biophysica acta. Reviews on cancer, 2023) Systematic review Relationship between Night Shifts and Risk of Breast Cancer among Nurses: A Systematic Review (Medicina (Kaunas, Lithuania), 2020) Clinical trial publication Efficacy of Melatonin in Alleviating Radiotherapy-Induced Fatigue, Anxiety, and Depression in Breast Cancer Patients: A Randomized, Triple-Blind, Placebo-Controlled Trial (Integrative cancer therapies, 2025) Clinical trial publication Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial (The oncologist, 2024) Clinical trial publication Identification of prognostic melatonin-related lncRNA signature in tumor immune microenvironment and drug resistance for breast cancer (Asian journal of surgery, 2023) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, Examine.com	PubChem Examine.com
Grape Seed Extract Natural product Clinical trial publication The effect of grape seed extract on estrogen levels of postmenopausal w… Clinical trial publication Role of multi-component functional foods in the complex treatment of pa…	Botanical	Phase II	Emerging	16	4 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT03092635 — AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy (TERMINATED) PHASE1 NCT00041223 — IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer (UNKNOWN) PHASE2 NCT00566553 — The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women (COMPLETED) NA NCT00100893 — IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer (COMPLETED) PHASE1 Published literature Clinical trial publication The effect of grape seed extract on estrogen levels of postmenopausal women: a pilot study (Journal of dietary supplements, 2014) Clinical trial publication Role of multi-component functional foods in the complex treatment of patients with advanced breast cancer (Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2007) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	—
Alpha-Lipoic Acid Natural product Clinical trial publication PREVENTION OF PACLITAXEL-INDUCED MOTOR NEUROPATHY OF FIBULAR AND TIBIAL… Clinical trial publication Randomized controlled trial of bromelain and alpha-lipoic acid in breas… Clinical trial publication EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREV…	Nutraceutical	Approved	Emerging	16	6 trials 8 Trial pubs 6 RCT View evidence Registry trials NCT07256119 — Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients (RECRUITING) NA NCT06406127 — Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients (UNKNOWN) PHASE4 NCT06703593 — Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients (COMPLETED) PHASE2 NCT01313117 — Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy (COMPLETED) PHASE1, PHASE2 NCT03908528 — Alpha-Lipoic Acid in Breast Cancer Patients (COMPLETED) NA NCT04161833 — Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) (COMPLETED) NA Published literature Clinical trial publication PREVENTION OF PACLITAXEL-INDUCED MOTOR NEUROPATHY OF FIBULAR AND TIBIAL NERVES WITH ALPHA-LIPOIC ACID AND IPIDACRIN HYDROCHLORIDE IN BREAST CANCER PATIENTS (Experimental oncology, 2025) Clinical trial publication Randomized controlled trial of bromelain and alpha-lipoic acid in breast conservative surgery (Scientific reports, 2025) Clinical trial publication EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES (Experimental oncology, 2022) Clinical trial publication Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833) (Medical oncology (Northwood, London, England), 2022) Clinical trial publication Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022) Randomized controlled trial EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE (Experimental oncology, 2022) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Calendula Officinalis Natural product Meta Analysis There is evidence to support the use of topical calendula for prophylax…	Nutraceutical	Phase III	Moderate	10	2 trials 2 RCT View evidence Registry trials NCT05073172 — StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients (WITHDRAWN) NA NCT01688479 — Trial Comparing Calendula Officinalis With Aqueous Cream "Essex" to Treat Skin Reactions From Radiotherapy of Breast Cancer (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
Omega-3 Fatty Acids Natural product Cochrane review The effectiveness of omega-3 fatty acids on health outcomes in women wi… Cochrane review Systemic therapies for preventing or treating aromatase inhibitor-induc… Cochrane review Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Re…	Nutraceutical	Phase III	Emerging	10	8 trials 6 Cochrane 24 Trial pubs 21 RCT View evidence Registry trials NCT02352779 — Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors (COMPLETED) NA NCT01849250 — Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors (COMPLETED) PHASE2 NCT00723398 — Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention (COMPLETED) NA NCT02278965 — Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer (COMPLETED) PHASE1 NCT03764943 — Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction (COMPLETED) PHASE3 NCT02996240 — Breast, Omega 3 Free Fatty Acid, Ph 0 (COMPLETED) NA NCT02517502 — Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy (COMPLETED) EARLY_PHASE1 NCT02150525 — Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors (COMPLETED) PHASE2 Published literature Cochrane review The effectiveness of omega-3 fatty acids on health outcomes in women with breast cancer: A systematic review (Food science & nutrition, 2023) Cochrane review Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer (The Cochrane database of systematic reviews, 2022) Cochrane review Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies (Advances in nutrition (Bethesda, Md.), 2020) Cochrane review Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis (Maturitas, 2018) Cochrane review Dietary supplements and fatigue in patients with breast cancer: a systematic review (Breast cancer research and treatment, 2018) Clinical trial publication The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial (The Journal of nutritional biochemistry, 2025) Clinical trial publication The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial (Nutrients, 2024) Clinical trial publication The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial (Clinical nutrition ESPEN, 2025) Clinical trial publication A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2 (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023) Clinical trial publication Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo (Cancer prevention research (Philadelphia, Pa.), 2021) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Folate Natural product Randomized controlled trial A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses… Randomized controlled trial A prospective study of serum folate levels in patients with solid tumor… Randomized controlled trial Low-dose daily folic acid (400 μg) supplementation does not affect regu…	Nutraceutical	Phase II	Emerging	10	8 trials 13 RCT View evidence Registry trials NCT01994369 — Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17) (COMPLETED) PHASE1 NCT03554109 — QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (WITHDRAWN) PHASE2 NCT05564377 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (RECRUITING) PHASE2 NCT01937507 — Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer (TERMINATED) PHASE2 NCT05579366 — Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (RECRUITING) PHASE1, PHASE2 NCT04300556 — A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (RECRUITING) PHASE1, PHASE2 NCT02419495 — Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (TERMINATED) PHASE1 NCT05891171 — Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ACTIVE_NOT_RECRUITING) PHASE1 Published literature Randomized controlled trial A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026) Randomized controlled trial A prospective study of serum folate levels in patients with solid tumors treated with olaparib (The oncologist, 2025) Randomized controlled trial Low-dose daily folic acid (400 μg) supplementation does not affect regulation of folate transporters found present throughout the terminal ileum and colon of humans: a randomized clinical trial (The American journal of clinical nutrition, 2024) Randomized controlled trial Circulating levels of MOTS-c in patients with breast cancer treated with metformin (Aging, 2022) Randomized controlled trial CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer (Nature communications, 2022) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Ginger Natural product Systematic review and network meta-analysis of the effects of plant act… Efficacy and Safety of Ginger on the Side Effects of Chemotherapy in Br… The effect of ginger (Zingiber officinale) on chemotherapy-induced naus…	Botanical	Preclinical	Emerging	10	3 trials View evidence Registry trials NCT04478630 — The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting (TERMINATED) NA NCT03449303 — Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention (COMPLETED) NA NCT06529458 — Effects of Acupressure and Aromatherapy on Nausea and Vomiting Severity, Anxiety and Comfort Level (NOT_YET_RECRUITING) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Garlic Natural product Cochrane review Medicinal Herbs Used in Traditional Management of Breast Cancer: Mechan… Meta-analysis Diet and cancer risk in the Korean population: a meta- analysis	Food compound	Preclinical	Emerging	10	2 trials 1 Cochrane 1 Meta-analysis 1 Trial pubs 1 RCT View evidence Registry trials NCT00079170 — Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer (COMPLETED) NA NCT03625635 — Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment (UNKNOWN) NA Published literature Cochrane review Medicinal Herbs Used in Traditional Management of Breast Cancer: Mechanisms of Action (Medicines (Basel, Switzerland), 2020) Meta-analysis Diet and cancer risk in the Korean population: a meta- analysis (Asian Pacific journal of cancer prevention : APJCP, 2014) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Olive Oil Natural product Randomized controlled trial Dietary patterns and change in food consumption in overweight or obese… Randomized controlled trial Efficacy of Topical Betamethasone Valerate and Olive Oil in Preventing… Randomized controlled trial Effect of Chamomile and Olive Oils on Volume, Range of Motion, and Qual…	Nutraceutical	Approved	Emerging	10	8 trials 10 RCT View evidence Registry trials NCT07440784 — Impact Of Intermittent And Water-Only Fasting On Gene Expression And Tumor Markers In Breast Cancer (ACTIVE_NOT_RECRUITING) NA NCT00627276 — Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia (COMPLETED) NA NCT02068092 — Olive Oil for High Risk Breast Cancer Prevention in Women (COMPLETED) PHASE2, PHASE3 NCT04818996 — Evaluation of the Effect of Mediterranean Diet on Breast Cancer Patients (COMPLETED) NA NCT07018986 — The MIND-BC Study: MIND Diet for Breast Cancer Cognition (RECRUITING) NA NCT05585476 — A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients. (NOT_YET_RECRUITING) NA NCT05285943 — Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients (COMPLETED) PHASE4 NCT04174391 — Lifestyles and Breast Cancer (ACTIVE_NOT_RECRUITING) NA Published literature Randomized controlled trial Dietary patterns and change in food consumption in overweight or obese breast cancer survivors: the InForma randomized intervention trial (Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026) Randomized controlled trial Efficacy of Topical Betamethasone Valerate and Olive Oil in Preventing Acute Radiation Dermatitis in Breast Cancer: A Randomized Double-Blind Placebo-Controlled Study (Clinical breast cancer, 2026) Randomized controlled trial Effect of Chamomile and Olive Oils on Volume, Range of Motion, and Quality of Life in Breast Cancer-Related Lymphedema: A Randomized Controlled Trial (Lymphatic research and biology, 2025) Randomized controlled trial Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial (Acta medica Indonesiana, 2023) Randomized controlled trial The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial (Clinical cancer research : an official journal of the American Association for Cancer Research, 2024) CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Ashwagandha Natural product Clinical trial publication Effect of Withania somnifera (Ashwagandha) on the development of chemot…	Ayurvedic	Preclinical	Emerging	7	1 Trial pubs View evidence Published literature Clinical trial publication Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients (Integrative cancer therapies, 2013) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Coenzyme Q10 Natural product Meta Analysis, Review CoQ10 supplementation reduced some of the important markers of inflamma… Human Study A combination of coenzyme Q10, riboflavin and niacin may improve outcom… Human Study Coenzyme Q10 supplementation could be effective in ameliorating inflamm…	Nutraceutical	Phase II	Emerging	7	6 trials View evidence Registry trials NCT02486796 — Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer (TERMINATED) PHASE1, PHASE2 NCT06137833 — Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy (RECRUITING) NA NCT00096356 — Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer (COMPLETED) PHASE1 NCT00976131 — Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer (COMPLETED) PHASE1 NCT07307911 — Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy (COMPLETED) PHASE2 NCT06570811 — Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Curcumin Natural product Cochrane review Systematic review and network meta-analysis of the effects of plant act… Cochrane review Therapeutic potency of curcumin on radiodermatitis: A systematic review Cochrane review Impact of Curcumin Supplementation on Radiation Dermatitis Severity: A…	Food compound	Phase III	Emerging	7	8 trials 4 Cochrane 3 Meta-analysis View evidence Registry trials NCT03482401 — Disposition of Dietary Polyphenols and Methylxanthines in Mammary Tissues From Breast Cancer Patients (COMPLETED) NA NCT03865992 — Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease (ACTIVE_NOT_RECRUITING) NA NCT01740323 — Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy (COMPLETED) PHASE2 NCT05306002 — Nutritional Intervention and DNA Damage of Patients With HBOC (COMPLETED) NA NCT03980509 — A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors (COMPLETED) PHASE1 NCT03072992 — "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer (COMPLETED) PHASE2 NCT01246973 — Oral Curcumin for Radiation Dermatitis (COMPLETED) PHASE2, PHASE3 NCT01975363 — Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer (COMPLETED) NA Published literature Cochrane review Systematic review and network meta-analysis of the effects of plant active substance on quality of life in breast cancer patients (Frontiers in pharmacology, 2025) Cochrane review Therapeutic potency of curcumin on radiodermatitis: A systematic review (Avicenna journal of phytomedicine, 2024) Cochrane review Impact of Curcumin Supplementation on Radiation Dermatitis Severity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Asian Pacific journal of cancer prevention : APJCP, 2023) Cochrane review In Vivo Efficacy and Toxicity of Curcumin Nanoparticles in Breast Cancer Treatment: A Systematic Review (Frontiers in oncology, 2021) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Berberine Natural product Meta Analysis, Review Berberine exerted anti-tumor effects in a variety of tumors in vivo.	Botanical	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Black Seed Oil Natural product Human In Vitro, Human Study Thymoquinone, a novel multi-strike inhibitor of pro-tumorigenic breast…	Botanical	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Egcg Natural product Human Study A presurgical study of lecithin formulation of green tea extract in wom…	Food compound	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Boswellia Natural product Human Study A Boswellia-based cream could be used for prevention of adjuvant radiot… Human Study A supplementation with Boswellia, betaine and myo-inositol reduces fibr…	Botanical	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Niacin Natural product Meta Analysis Vitamin supplement use during breast cancer treatment and survival redu… Human Study A combination of coenzyme Q10, riboflavin and niacin may improve outcom…	Nutraceutical	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Ginseng Natural product Human Study African-American diagnosed with breast cancer are 1.6 times more likely… Human Study An increased intake of some fruits, vegetables, and soy foods may be as…	Botanical	Preclinical	Emerging	7	—	GreenMedInfo	GreenMedInfo
Chamomile Natural product Effect of Chamomile and Olive Oils on Volume, Range of Motion, and Qual… Comparison of liposomal gel with and without chamomile to prevent radia… Efficacy of an aloe vera, chamomile, and thyme cosmetic cream for the p…	Botanical	Preclinical	Emerging	7	—	GreenMedInfo	GreenMedInfo
Multivitamin Natural product Meta Analysis, Review CoQ10 supplementation reduced some of the important markers of inflamma… Meta Analysis Vitamin supplement use during breast cancer treatment and survival redu… Human In Vitro, Human Study Thymoquinone, a novel multi-strike inhibitor of pro-tumorigenic breast…	Nutraceutical	Preclinical	Emerging	7	—	GreenMedInfo	GreenMedInfo
Staurosporine Natural product Calcitonin Receptor is a Novel Biomarker for NF-κB-Mediated Cellular St… Investigation of beetroot (Beta Vulgaris) extracts compared to staurosp… Unveiling the cytotoxic potential of four Callistemon fruit extracts ag…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
9-benzyl-9h-adenine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
7H-adenine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Gsk-690693 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Ruboxistaurin Natural product Protein kinase C-beta as a therapeutic target in breast cancer	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Medroxyprogesterone Acetate Natural product Long-term hormone therapy for perimenopausal and postmenopausal women Depot medroxyprogesterone acetate and breast cancer: a systematic review Effects of Estradiol/Micronized Progesterone vs. Conjugated Equine Estr…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Progesterone Natural product Genomic landscape of triple-negative breast cancer in South Asian popul… Immune checkpoint inhibitors and chemotherapy versus chemotherapy for e… From tumor microenvironment orchestrators to actionable targets: a syst…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Prednisolone Natural product Refractory and Recurrent Idiopathic Granulomatous Mastitis Treatment: A… Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone… Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a m…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Stanolone Natural product Unoccupied binding sites for oestradiol in nuclei from human breast car… Anovulation and increased androgenic activity as breast cancer risk in… Steroid sex hormones and prolactin in postmenopausal women with general…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Mifepristone Natural product A randomized phase II trial of nab-paclitaxel with or without mifeprist… Transcriptomic Profile of Breast Tissue of Premenopausal Women Followin… Antiprogestins reduce epigenetic field cancerization in breast tissue o…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Thiourea Natural product Hybridization of isatin and benzoxazolinone via a diethyl spacer: a new… Synthesis and Biological Activity of Guanidine Scaffold: A Comprehensiv… Organoruthenium(II) complexes with adamantane-thiourea ligands: structu…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Dactolisib Natural product Drug repurposing identifies novel Wee1 kinase inhibitors for triple neg… Synergistic effect of Dactolisib/Lys05 combination on autophagy in A549… Combination of Conventional Drugs with Biocompounds Derived from Cinnam…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Indigotindisulfonate Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Nifedipine Natural product Calcium channel blockers and breast cancer incidence: An updated system… Calcium channel blockers and risk of breast cancer: a meta-analysis of… Angiotensin-converting enzyme inhibitors, calcium channel blockers, and…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
5,7-dihydroxy-3-(4-hydroxyphenyl)chromone Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
2-methyl-4,5-dimethylol-pyridin-3-ol;hydrochloride Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
5,7-dihydroxy-3-(4-hydroxyphenyl)chromone;7-hydroxy-3-(4-hydroxyphenyl)chromone;7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-chromone Natural product Human Study A combination of hydroxytyrosol, omega-3 fatty acids and curcumin impro…	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
Bilberry Natural product Bilberry (Vaccinium myrtillus L.) Peel-Enriched Pomace as Natural Antic… The Action Mechanisms, Anti-Cancer and Antibiotic-Modulation Potential… Anthocyanidins Inhibit Growth and Chemosensitize Triple-Negative Breast…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fruit: All Natural product Meta Analysis, Review Fruit and vegetable consumption can reduce the incident breast cancer. Human Study A high intake of some fruits, vegetables, and soybeans may be associate… Human Study Adherence to a diet comprising mostly fruits, vegetables, fish, and oli…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Vegetables: All Natural product Meta Analysis, Review Fruit and vegetable consumption can reduce the incident breast cancer. Human Study A high intake of some fruits, vegetables, and soybeans may be associate… Human Study Adherence to a diet comprising mostly fruits, vegetables, fish, and oli…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Soy Natural product Human Study A high intake of some fruits, vegetables, and soybeans may be associate… Human Study Among women with breast cancer, soy food consumption was significantly… Human Study An increased intake of some fruits, vegetables, and soy foods may be as…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Flaxseed Natural product Meta Analysis Flax and Breast Cancer: A Systematic Review.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Coffee Natural product Meta Analysis Coffee consumption is associated with decreased risk of postmenopausal… Human Study Chlorogenic acids-present in coffee, fruits, and vegetables-was associa… Human Study Coffee and caffeine may be associated with improved capacity to efficie…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fiber Natural product Meta Analysis, Review Dietary fibre consumption is significantly associated with a reduced ri… Human Study A high dietary intake of bean fiber and fiber-rich foods such as beans…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Homeopathic Medicine: All Natural product Meta Analysis There is evidence to support the use of topical calendula for prophylax… Human Study A. montana 1000 K could reduce post-operative blood and seroma collecti…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cruciferous Vegetables Natural product Human Study A high intake of some fruits, vegetables, and soybeans may be associate… Human Study Adherence to a diet comprising mostly fruits, vegetables, fish, and oli… Human Study An increased intake of some fruits, vegetables, and soy foods may be as…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Apples Natural product Meta Analysis Consumption of apples is associated with a reduced risk of cancer in di…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
EGCG (Epigallocatechin Gallate) Natural product Human Study A presurgical study of lecithin formulation of green tea extract in wom…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Betaine Natural product Human Study A supplementation with Boswellia, betaine and myo-inositol reduces fibr…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Chokeberry Natural product Human Study A. melanocarpa may be regarded as a promising new source of bioactive a…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Beta-Glucan Natural product Human Study Beta glucan has beneficial immunomodulatory effects in women with breas…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Phytoestrogens Natural product Human Study Breast cancer survivors who use estrogenic botanical supplements have l…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fermented Foods and Beverages Natural product Meta Analysis, Review Consumption of fast foods and ultra-processed foods and breast cancer r… Human Study A 10% increase in the proportion of ultra-processed foods in the diet w… Human Study A high dietary intake of bean fiber and fiber-rich foods such as beans…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Caffeine Natural product Human Study Coffee and caffeine may be associated with improved capacity to efficie…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Onion Natural product Human Study Consumption of fresh yellow onion ameliorates hyperglycemia and insulin…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Catechin Natural product Green Tea Catechin Extract Supplementation Does Not Influence Circulati… Effects of green tea catechin extract on serum lipids in postmenopausal… The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Isoflavones Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Beta-Carotene Natural product Human Study Beta glucan has beneficial immunomodulatory effects in women with breas…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Legumes Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Kefir Natural product Meta Analysis, Review Bioactive compounds from kefir and their potential benefits on health.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Flavonoids Natural product Meta Analysis The present study suggests the intake of flavonols and flavones is asso…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Calendula Natural product Meta Analysis There is evidence to support the use of topical calendula for prophylax…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Homeopathic Medicine: Traumeel Natural product Meta Analysis There is evidence to support the use of topical calendula for prophylax… Human Study A. montana 1000 K could reduce post-operative blood and seroma collecti…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Linoleic Acid Natural product Meta Analysis This meta-analysis indicated that both dietary linoleic acid intake and…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lavender Natural product Meta Analysis This meta-analysis of 10 RCTs reveals that aromatherapy with single ess…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Antioxidant Formulas Natural product Meta Analysis Vitamin supplement use during breast cancer treatment and survival redu… Human Study A. melanocarpa may be regarded as a promising new source of bioactive a…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Gc Protein-Derived Macrophage Activating Factor (GcMAF) Natural product Meta Analysis, Review Induced abortion as an independent risk factor for breast cancer. Meta Analysis Higher total red meat, fresh red meat, and processed meat intake may be… Meta Analysis Sedentary behavior was validated as a risk factor of breast cancer thro…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Riboflavin (Vitamin B-2) Natural product Meta Analysis Vitamin supplement use during breast cancer treatment and survival redu… Human Study A combination of coenzyme Q10, riboflavin and niacin may improve outcom…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Hydroxytyrosol Natural product Human Study A combination of hydroxytyrosol, omega-3 fatty acids and curcumin impro…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Beans: All Natural product Human Study A high dietary intake of bean fiber and fiber-rich foods such as beans… Human Study A high intake of some fruits, vegetables, and soybeans may be associate…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Maitake Mushroom Natural product Human Study A phase I/II trial of a polysaccharide extract from Maitake mushroom in…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cyclohexane-1,2,3,4,5,6-Hexol Natural product Human Study A supplementation with Boswellia, betaine and myo-inositol reduces fibr…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network